0001493152-23-026996.txt : 20230807 0001493152-23-026996.hdr.sgml : 20230807 20230807134321 ACCESSION NUMBER: 0001493152-23-026996 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230807 DATE AS OF CHANGE: 20230807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BLUE BIOFUELS, INC. CENTRAL INDEX KEY: 0001549145 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 454944960 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54942 FILM NUMBER: 231146816 BUSINESS ADDRESS: STREET 1: 3710 BUCKEYE ST STREET 2: SUITE 120 CITY: PALM BEACH GARDENS STATE: FL ZIP: 33401 BUSINESS PHONE: (888)607-3555 MAIL ADDRESS: STREET 1: 3710 BUCKEYE ST STREET 2: SUITE 120 CITY: PALM BEACH GARDENS STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: ALLIANCE BIOENERGY PLUS, INC. DATE OF NAME CHANGE: 20141204 FORMER COMPANY: FORMER CONFORMED NAME: Alliance Media Group Holdings, Inc. DATE OF NAME CHANGE: 20120504 10-Q 1 form10-q.htm
0001549145 false --12-31 Q2 true false 0001549145 2023-01-01 2023-06-30 0001549145 2023-08-05 0001549145 2023-06-30 0001549145 2022-12-31 0001549145 us-gaap:NonrelatedPartyMember 2023-06-30 0001549145 us-gaap:NonrelatedPartyMember 2022-12-31 0001549145 us-gaap:RelatedPartyMember 2023-06-30 0001549145 us-gaap:RelatedPartyMember 2022-12-31 0001549145 2023-04-01 2023-06-30 0001549145 2022-04-01 2022-06-30 0001549145 2022-01-01 2022-06-30 0001549145 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001549145 us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001549145 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001549145 us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001549145 us-gaap:CommonStockMember 2022-12-31 0001549145 us-gaap:PreferredStockMember 2022-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001549145 us-gaap:RetainedEarningsMember 2022-12-31 0001549145 us-gaap:CommonStockMember 2023-03-31 0001549145 us-gaap:PreferredStockMember 2023-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001549145 us-gaap:RetainedEarningsMember 2023-03-31 0001549145 2023-03-31 0001549145 us-gaap:CommonStockMember 2021-12-31 0001549145 us-gaap:PreferredStockMember 2021-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001549145 us-gaap:RetainedEarningsMember 2021-12-31 0001549145 2021-12-31 0001549145 us-gaap:CommonStockMember 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-03-31 0001549145 2022-03-31 0001549145 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001549145 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001549145 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001549145 2023-01-01 2023-03-31 0001549145 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001549145 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001549145 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001549145 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001549145 2022-01-01 2022-03-31 0001549145 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001549145 us-gaap:CommonStockMember 2023-06-30 0001549145 us-gaap:PreferredStockMember 2023-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001549145 us-gaap:RetainedEarningsMember 2023-06-30 0001549145 us-gaap:CommonStockMember 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-06-30 0001549145 2022-06-30 0001549145 BIOF:IssuanceDateFebruaryTenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateMarchOneTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateAprilFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateAprilElevenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateFebruaryTenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateMarchOneTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateAprilFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateAprilElevenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateJuneFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateJulyThirteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateJuneFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateJulyThirteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 srt:MinimumMember 2023-06-30 0001549145 srt:MaximumMember 2023-06-30 0001549145 us-gaap:BuildingImprovementsMember 2023-06-30 0001549145 us-gaap:BuildingImprovementsMember 2022-12-31 0001549145 us-gaap:MachineryAndEquipmentMember 2023-06-30 0001549145 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001549145 us-gaap:FurnitureAndFixturesMember 2023-06-30 0001549145 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001549145 us-gaap:ComputerEquipmentMember 2023-06-30 0001549145 us-gaap:ComputerEquipmentMember 2022-12-31 0001549145 BIOF:PilotPlantMember 2023-01-01 2023-06-30 0001549145 BIOF:MachineryMember 2023-01-01 2023-06-30 0001549145 BIOF:MachineryMember 2023-06-30 0001549145 BIOF:OfficeAndLaboratorySpaceMember 2023-01-01 2023-06-30 0001549145 2020-09-01 0001549145 2020-09-01 2020-09-01 0001549145 us-gaap:SubsequentEventMember BIOF:SBIRPhaseIGrantMember 2023-07-01 2023-07-01 0001549145 us-gaap:SubsequentEventMember 2023-07-01 2023-07-01 0001549145 us-gaap:SubsequentEventMember srt:MinimumMember 2023-07-01 2023-07-01 0001549145 us-gaap:SubsequentEventMember srt:MaximumMember 2023-07-01 2023-07-01 0001549145 us-gaap:SubsequentEventMember us-gaap:RelatedPartyMember 2023-07-01 0001549145 us-gaap:SubsequentEventMember us-gaap:RelatedPartyMember 2023-07-01 2023-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:acre

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarter ended June 30, 2023

 

Commission File Number: 000-54942

 

BLUE BIOFUELS, INC.

(Exact name of small Business Issuer as specified in its charter)

 

Nevada   45-4944960
(State or other jurisdiction   (IRS Employer
of incorporation or organization)   Identification No.)

 

3710 Buckeye Street, Suite 120    
Palm Beach Gardens, FL   33410
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 607-3555

 

n/a

Former name or former address if changed since last report

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Securities registered pursuant to Section 12(g) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock par value $0.001   BIOF   OTCQB

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒.

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer Emerging Growth Company
    Smaller reporting company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

The aggregate market value of the voting stock held by non-affiliates of the registrant as of the last business day of the registrant’s most recently completed second fiscal quarter was $29,189,366.

 

State the number of shares outstanding of the registrant’s $.001 par value common stock as of the close of business on the latest practicable date August 5, 2023): 301,084,297.

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
  PART I—FINANCIAL INFORMATION  
     
ITEM 1. Consolidated Financial Statements (unaudited)  
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 23
ITEM 4. Controls and Procedures 23
     
  PART II—OTHER INFORMATION  
     
ITEM 1. Legal Proceedings 24
ITEM 1A. Risk Factors 24
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 24
ITEM 3. Defaults Upon Senior Securities 25
ITEM 4. Mine Safety Disclosures 25
ITEM 5. Other Information 25
ITEM 6. Exhibits 25
  Signatures 26

 

2

 

 

PART I – FINANCIAL INFORMATION

 

TABLE OF CONTENTS

 

Index to Financial Statements   Page
Condensed Consolidated Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022   4
     
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2023 and 2022 (unaudited)   5
     
Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2023 and 2022 (unaudited)   6
     
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022 (unaudited)   7
     
Notes to Condensed Consolidated Financial Statements (unaudited)   8

 

3

 

 

Blue Biofuels, Inc.

Financial Statements

Period Ended June 30, 2023

 

UNAUDITED FINANCIAL STATEMENTS

OF

BLUE BIOFUELS, INC.

 

Blue Biofuels, Inc.

CONSOLIDATED BALANCE SHEETS

(unaudited)

 

   June 30, 2023   December 31, 2022 
ASSETS          
Current assets          
Cash and cash equivalents  $61,677   $211,901 
Prepaid expenses   61,118    43,119 
TOTAL CURRENT ASSETS  $122,795   $255,020 
Other assets          
Property and equipment, net of accumulated depreciation and amortization of $184,283 and $127,178 at June 30, 2023 and December 31,2022, respectively   642,100    420,115 
Security deposits   30,276    30,276 
Right of Use Assets, net of accumulated amortization   129,745    178,399 
Patents   234,730    222,109 
TOTAL OTHER ASSETS  $1,036,851   $850,899 
TOTAL ASSETS  $1,159,646   $1,105,919 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities          
Accounts payable  $14,735   $37,135 
Accounts payable - Related Party   72,670   $72,670 
Deferred wages and director’s fees - Related party   638,076   $307,606 
Lease Liability - Current   99,626   $95,172 
Chapter 11 Settlement   -    50,000 
Convertible Notes Payable — Related Party   350,000    - 
Interest Payable - Related Party   102,718    76,138 
TOTAL CURRENT LIABILITIES  $1,277,825   $638,721 
Long term liabilities          
Right of Use Lease Liability, net of current portion   34,909    85,983 
Notes Payable — Related Party   2,721,562    2,521,562 
Notes Payable — Other   216,570    216,570 
TOTAL LONG TERM LIABILITIES  $2,973,041   $2,824,115 
TOTAL LIABILITIES  $4,250,866   $3,462,836 
           
STOCKHOLDERS’ EQUITY (DEFICIT)          
Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding   -    - 
Common stock; $0.001 par value; 1,000,000,000 shares authorized; 300,584,297 issued and outstanding at June 30, 2023, and 289,941,623 shares issued and outstanding at December 31, 2022.   300,584    289,942 
Additional paid-in capital   51,608,070    50,134,727 
Accumulated deficit   (54,999,875)   (52,781,586)
Total stockholders’ equity (deficit)  $(3,091,221)  $(2,356,917)
TOTAL EQUITY (DEFICIT)  $(3,091,221)  $(2,356,917)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $1,159,646   $1,105,919 

 

4

 

 

Blue Biofuels, Inc

CONSOLIDATED STATEMENT OF OPERATIONS

(unaudited)

 

   2023   2022   2023   2022 
   Three Months Ended   Six Months Ended 
   30-Jun   30-Jun 
   2023   2022   2023   2022 
Revenues  $-   $-   $-   $- 
Operating expense:                    
General and administrative   355,324    241,507    725,169    1,044,571 
Research & Development   762,714    436,480    1,447,276    1,666,632 
Loss on disposal of assets   -    40,099    369    40,099 
Total operating expenses   1,118,038    718,086    2,172,813    2,751,302 
                     
Loss from operations:   (1,118,038)   (718,086)   (2,172,813)   (2,751,302)
                     
Other (income) expense:                    
Interest expense - related party   33,783    6,712    40,495    13,424 
Interest expense - other   2,378    592    4,981    1,621 
Total other (income) expense   36,161    7,304    45,475    15,045 
                     
Income (Loss) before provisions for income taxes  $(1,154,199)  $(725,390)  $(2,218,288)  $(2,766,347)
Provisions for income taxes   -    -           
Net Income / (Loss):  $(1,154,199)  $(725,390)  $(2,218,288)  $(2,766,347)
                     
Net income (loss) per share  $(0.004)  $(0.003)  $(0.007)  $(0.010)
                     
Net income (loss) per share, fully diluted  $(0.003)  $(0.002)  $(0.006)  $(0.008)
                     
Weighted average common shares outstanding                    
Basic   297,635,565    275,876,745    297,635,565    275,876,745 
Fully Diluted   351,822,695    331,481,205    351,822,695    331,481,205 

 

5

 

 

Blue Biofuels, Inc.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

 

   Shares   Amount   Shares   Amt   Capital   Deficit   (Deficit) 
   Common Stock   Preferred Stock   Additional Paid-in   Accumulated   Total Stockholder’s 
   Shares   Amount   Shares   Amt   Capital   Deficit   (Deficit) 
Balance as of December 31, 2022   289,941,623   $289,942    -    -   $50,134,727   $(52,781,586)  $(2,356,917)
Issuance of common stock for services   140,000   $140    -    -   $23,860    -   $24,000 
Issuance of common stock and warrants for cash through PPM   3,884,998   $3,885    -    -   $578,865    -   $582,750 
Warrants exercised   5,450,148   $5,450    -    -   $66,800    -   $72,250 
Vesting of 2,385,000 options under the employee, director plan             -    -   $391,297    -   $391,297 
Net Income (Loss)                            (1,064,090)  $(1,064,090)
Balance as of March 31, 2023   299,416,769   $299,417    -    -   $51,195,549   $(53,845,676)  $(2,350,710)
Issuance of common stock for services   34,194    34    -    -    5,266    -    5,300 
Vesting of 2,000,000 options under the employee, director plan             -    -    245,732    -    245,732 
Issuance of common stock and warrants for cash through PPM   633,334    633    -    -    94,389    -    95,022 
Issuance of 314,000 warrants for services             -    -    42,634    -    42,634 
Warrants exercised   500,000    500    -    -    24,500    -    25,000 
Net Income (Loss)                            (1,154,199)   (1,154,199)
Balance as of June 30, 2023   300,584,297   $300,584    -    -   $51,608,069   $(54,999,875)  $(3,091,221)
                                    
Balance as of December 31, 2021   274,003,883   $274,004    -    -   $47,151,353   $(48,821,403)  $(1,396,046)
Issuance of common stock for services   447,781   $448    -    -   $70,852    -   $71,300 
Employee stock options exercised   150,000   $150    -    -   $7,350    -   $7,500 
Vesting of 10,560,000 options under the employee, director plan             -    -   $1,316,277    -   $1,316,277 
Net Income (Loss)                            (2,040,957)  $(2,040,957)
Balance as of March 31, 2022   274,601,664   $274,602    -    -   $48,545,832   $(50,862,360)  $(2,041,926)
Issuance of common stock for services   78,600   $79    -    -   $16,071    -   $16,150 
Employee stock options exercised   200,000    200    -    -    8,200    -    8,400 
Vesting of 800,000 options under the employee, director plan             -    -    99,106    -    99,106 
Issuance of common stock and warrants for cash through PPM   4,499,999    4,500    -    -    670,500    -    675,000 
Net Income (Loss)                            (725,390)   (725,390)
Balance as of June 30, 2022   279,380,263   $279,380    -    -   $49,339,710   $(51,587,750)  $(1,968,660)

 

6

 

 

Blue Biofuels, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   For the Six Months
Ended
   For the Six Months
Ended
 
   30-Jun-23   30-Jun-22 
Cash flows from operating activities          
Net Income (Loss)  $(2,218,288)  $(2,766,347)
Reconciliation of net loss to net cash used in operating activities          
Depreciation and amortization   59,684    68,123 
Stock based compensation for services   29,300    87,450 
Net Issuance of options and warrants for services   679,662    1,415,383 
Extinguishment of Debt   (50,000)     
Loss on Disposal of assets   369    40,099 
Changes in operating assets and liabilities          
Prepaid expenses   (18,000)   (66,896)
Accrued interest - related party   26,581    13,424 
Accounts payable and accrued liabilities   308,070    45,753 
Right of use lease   2,035    (42,974)
Net cash used in operating activities   (1,180,587)   (1,205,985)
           
Cash flows from investing activities          
Net Purchase of property and equipment   (282,038)   (2,400)
Security deposits   -    - 
Patent Costs   (12,621)   (18,273)
Net cash from (used in) investing activities   (294,659)   (20,673)
           
Cash flows from financing activities          
Proceeds from exercise of warrants and options   97,250    15,900 
Net Proceeds from the issuance of Convertible Notes   550,000      
Net proceeds from issuance of common stock   677,772    675,000 
Net cash provided by financing activities   1,325,022    690,900 
           
Net increase (decrease) in cash and cash equivalents   (150,224)   (535,758)
           
Cash and cash equivalent at beginning of the period   211,901    1,164,664 
Cash and cash equivalent at end of the period  $61,677   $628,906 
           
Supplemental disclosure of cash flow information          
Cash paid during the period for          
Interest  $-   $- 
Taxes  $-   $- 
           
Supplemental schedule of non-cash activities          
Cashless conversion of warrants/options  $-   $- 
Conversion of convertible debenture to common stock  $-   $- 

 

7

 

 

Blue Biofuels, Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – ORGANIZATION

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.

 

In early 2018, the Company’s chief executive officer (“CEO”) Ben Slager invented a new technology system referred to as Cellulose-to-Sugar or CTS, and the Company filed a process patent application for this technology. Mr. Slager has since further developed the system with laboratory personnel. The CTS patent was awarded in 2021 in the United States (U.S. Patent No. 10,994,255) and also in El Salvador. The Company also filed this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, Japan, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. In addition to this patent, the Company has received one additional patent (for which it has also applied for in all the above-mentioned jurisdictions). Further, the company has filed for 4 other patents which are currently pending.

 

Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for breaking down cellulosic material for conversion into biofuels. CTS can break down any cellulosic material – including grasses and agricultural waste. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.

 

CTS is environmentally friendly in that it recycles the water and catalyst, and it has a low carbon footprint: the amount of added atmospheric carbon created by burning the biofuels produced by the CTS system was absorbed by the plant-based feedstock while growing and is merely released back into the atmosphere. No extra CO2 is released into the atmosphere when our biofuels are burned. This is to be distinguished from fossil fuels because new CO2 is released when fossil fuels are burned.

 

At a commercial scale, our management expects to be able to produce ethanol at a lower cost per gallon than existing commercial corn or cellulosic ethanol producers due to the fact that the CTS process is robust, uncomplicated and efficient, and is expected to use low-cost feedstocks and have a potentially high value by-product, lignin. We believe a significant difference between CTS ethanol and corn ethanol is the wide range of abundantly available feedstocks that CTS can process compared to just corn as the feedstock. The CTS feedstocks are nonfood and have much lower costs than corn. In addition, while in corn ethanol only the corn kernels are used, CTS uses the whole plant or its waste products, meaning it could obtain much higher yields per acre. The Company also expects to potentially receive a highly valued D3 RIN for each gallon of ethanol it produces.

 

The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.

 

In 2022, the Company partnered with K.R. Komarek to build its CTS machines going forward. In 2023, the Company completed the build-out of a pilot plant based on a modified Komarek machine and is in the process of further testing and optimizing the plant. Komarek is an industry leading manufacturing company that builds briquetting machines and compaction/granulation systems with throughput capacities up to 50 tons per hour.

 

The Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF). The license agreement with Vertimass is the subject to a confidentiality agreement between the parties.

 

8

 

 

Plan of Operation

 

The Company will prioritize building an SAF facility to generate revenue sooner. First, the Company intends to build a commercial scale ethanol to SAF facility and subsequently build commercial CTS and ethanol facilities on the front-end of that to produce cellulosic SAF and generate the large D7 RIN and other government credits.

 

Commencing commercial production will require project financing. The project financing is planned to initially be for setting up a 10 million gallon per year production facility for converting ethanol into jet fuel using the Vertimass Process that the Company has licensed. Parallel to that, the Company plans to build a semicommercial CTS demonstration plant that integrates a larger CTS system into the pre-processing and post-processing elements of the plant. The goal of the semi-commercial plant is to finalize design and operational parameters at this volume level and to provide operating cost estimates of a full commercial volume system. Due to its mechanical nature and modularity, we anticipate that one plant would have multiple modular CTS systems.

 

After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the technology or forming joint ventures with foreign domestic partners to build plants.

 

The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as the feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic suppliers, we anticipate that our profitability will be more consistent.

 

Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.

 

The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (EPA), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.02 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.

 

Section 45Z of the Inflation Reduction Act passed on August 16, 2022, offers a Clean Fuel Production Credit (CFPC) per gallon of transportation fuel produced with a base amount of 20 cents per gallon or $1 per gallon for a qualified facility that was built while paying at least prevailing wages and which met apprenticeship requirements. For sustainable aviation fuel, those figures are 35 cents and $1.75 per gallon respectively. The Company plans to apply for CFPC credits when it begins building its commercial facilities. The CFPC currently does not apply to transportation fuel sold after December 31, 2027. 

 

A Low Carbon Fuel Standard Credit (LCFS) is offered by various states (primarily California) for any amount of reduced CO2 in the production lifecycle of transportation fuels as compared to the amount of CO2 emitted in the production lifecycle of fossil fuels. The production lifecycle includes transportation costs to the point of use. California is currently offering around $72.50 per metric ton of CO2 reduction. When it is closer to commercial production, the Company plans to analyze the cost effectiveness of applying for these LCFS credits to determine in which state it could earn the most credits.

 

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has not generated any material revenues from its business.

 

9

 

 

NOTE 2 – GOING CONCERN

 

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of June 30, 2023, the Company has incurred accumulated losses of $54,999,875. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. These factors, among others, raise substantial doubt as to the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.

 

Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities, and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, or sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our supply chain, employees, and potential future customers. Our office and lab have remained open during the pandemic. Nevertheless, the pandemic slowed our ability to commercialize our process in two ways: by adversely affecting our ability to raise capital, and by adversely affecting the supply chain of laboratory equipment and various parts of upgrades to our CTS system, which slowed the development of our prototypes. Supply chain issues also delayed the delivery of various parts of our pilot plant. The extent to which our operations may be further impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the effects of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

 

10

 

 

Cash and Cash Equivalents

 

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

 

Stock Compensation

 

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

 

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

 

The stock compensation issued for services during the quarter ended June 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the quarter ended June 30, 2023:

 

   2/10/23   2/14/23   3/1/23   3/31/23   4/5/23   4/11/23 
Risk-free interest rate   3.93%   3.77%   4.01%   3.60%   3.30%   3.54%
Expected life   5 years    10 years    10 years    5 years    10 years    5 years 
Expected dividends   0%   0%   0%   0%   0%   0%
Expected volatility   123.25%   123.26%   123.52%   120.71%   119.51%   119.39%
BIOF common stock fair value  $0.159   $0.159   $0.177   $0.166   $0.154   $0.145 

 

   4/26/23   6/5/23   7/13/23 
Risk-free interest rate   3.46%   3.82%   3.82%
Expected life   5 years    7 years    5 years 
Expected dividends   0%   0%   0%
Expected volatility   119.28%   103.20%   90.70%
BIOF common stock fair value  $0.165   $0.170   $0.160 

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 

Patent Capitalization

 

If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $234,730 as of June 30, 2023 and $222,109 as of December 31, 2022.

 

Research and Development

 

The Company expenses all research and development costs as incurred. For the six months ended June 30, 2023, and June 30, 2022, the amounts charged to research and development expenses were $1,447,276 and $1,666,632, respectively.

 

Revenue Recognition

 

The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:

 

  1. persuasive evidence of an arrangement exists;
  2. the product has been shipped or the services have been rendered to the customer;
  3. the sales price is fixed or determinable; and,
  4. collectability is reasonably assured.

 

11

 

 

Common Stock Purchase Warrants and Other Derivative Financial Instruments

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Profit (Loss) per Common Share:

 

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

 

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

 

NOTE 4 – PROPERTY AND EQUIPMENT

 

PROPERTY AND EQUIPMENT  Life  June 30, 2023   December 31, 2022 
Building and Improvements  15  $9,370   $9,370 
Machinery and Equipment  10  $791,540   $512,450 
Furniture and Fixtures  5  $13,649   $13,649 
Computer Equipment  3  $11,824   $11,824 
Property and Equipment, gross     $826,383   $547,293 
Less Accumulated Depreciation     $(184,283)  $(127,178)
Property and Equipment     $642,100   $420,115 

 

Total depreciation expense was $59,684 for the six months ended June 30, 2023.

 

In the six months ended June 30, 2023, The Company purchased machinery worth $285,538. This was primarily related to the pilot plant. The Company disposed of machinery that was no longer in use for a total of $3,500 that originally was purchased for $6,448 and that had accumulated depreciation of $2,579, thereby taking a loss of $369 on the disposal of assets.

 

12

 

 

NOTE 5 – PATENTS

 

The Company has been granted one patent on its technology and one continuation patent, has filed for three others that are pending, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $234,730 as of June 30, 2023.

 

NOTE 6 – DEBT

 

Notes Payable – Related Parties

 

In July 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $25,000, that is to be repaid when the Company receives an equity investment of at least $3 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 every 12 months instead of interest, with a minimum of 50,000 warrants. It may convert into common stock at $0.13/share at the option of the holder for a total of 192,308 shares.

 

In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $50,000, that is to be repaid when the Company receives $5 million in equity investment. The Note carries a 10% interest per annum. The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants.

 

In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $100,000, that if it’s not paid by December 6, 2023, it automatically extends for another 6 months. It’s convertible at the option of the lender into common stock at $0.13/share for a total of 769,231 shares.

 

In April 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $150,000, that is to be repaid when the Company receives an equity investment of at least $1.5 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 100,000 every 6 months instead of interest. It may convert into common stock at $0.13/share at the option of the holder for a total of 1,153,846 shares.

 

In January 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $250,000, that if it’s not paid by July 4, 2023, it converts at the option of the Company into common stock at $0.13/share for a total of 1,923,077 shares.

 

In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the notes was $278,794.68. The notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, & Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company.

 

On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of future gross revenues to satisfy this note in full.

 

13

 

 

On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

Notes Payable – Other

 

In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the note was $14,382.2. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.

 

In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carried an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $39,500. In May 2018, the company made two principal payments totaling $40,000. The note went into default on June 1, 2018, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company.

 

In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to settle both notes.

 

14

 

 

On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $32,000 to $20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019.

 

A summary of all debts indicated in the Notes above is as follows:

 

Notes Payable 

June 30, 2023

  

December 31, 2022

 
Short Term Convertible Note – Related Party  $350,000   $0 
Short Term Chapter 11 Settlement  $0   $50,000 
Long Term Notes Payable after capital investment received  $200,000   $0 
Long Term Notes Payable from future revenue — Related Party  $1,700,630   $1,700,630 
Long Term Notes Payable from future revenue — Other  $120,000   $120,000 
Long Term Note Payable from future profits — Related Party  $820,932   $820,932 
Long Term Note Payable from future profits — Other  $96,570   $96,570 
TOTAL NOTES  $3,288,132   $2,788,132 

 

Of the $3,288,132 payable as of June 30, 2023, $2,738,132 is due out of future revenue or future profits with no specific due date, and another $200,000 is due only after a significant capital investment. $2,417,502 of the $2,788,132 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would not be discharged is $670,630, consisting of $550,630 due to related parties, and $120,000 due to others.

 

NOTE 7 – STOCKHOLDERS’ EQUITY

 

The total number of shares of capital stock, which the Company has authority to issue, is 1,010 million, 1 billion of which are designated as common stock at $0.001 par value (the “Common Stock”) and 10 million of which are designated as preferred stock par value $0.001 (the “Preferred Stock”). As of June 30, 2023, the Company had 300,584,297 shares of Common Stock issued and outstanding and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.

 

For the six months ended June 30, 2023, the Company issued an aggregate of 174,191 shares of its common stock for services valued at $29,300.

 

For the six months ended June 30, 2023, 314,000 warrants were issued for services. Using a Black-Scholes asset pricing model, these had a value of $42,634.

 

For the six months ended June 30, 2023, 4,518,332 shares of common stock were issued for cash of $677,771.

 

For the six months ended June 30, 2023, 5,950,148 warrants were exercised for proceeds of $97,250.

 

For the six months ended June 30, 2023, 2,067,999 warrants expired.

 

For the six months ended June 30, 2023, 7,050,000 unvested options expired.

 

For the six months ended June 30, 2023, 4,385,000 stock options vested. Using a Black-Scholes asset pricing model, these had a value of $637,028.

 

For the six months ended June 30, 2023, 15,950,000 stock options were issued and unvested. Using a Black-Scholes asset pricing model, these have a value of $2,675,116.

 

15

 

 

NOTE 8 - COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. The Company is not in any litigation at this time.

 

Leases

 

The Company currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period was for twenty-four (24) months from November 1, 2019, to October 31, 2021. This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024. Annual rent commenced at $84,100 per annum and increased 3% per year. The latest amendment adjusted to lease to $102,950 per annum and increases at 3% per year. Tenant is also required to cover operating costs that are estimated at $3,600 per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General & Administrative expenses.

 

ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

 

In addition, the Company leases land in Arcadia, FL where it grows king grass. The original lease began on September 1, 2020, and was for 18.2 acres at an annual cost of $6,370 that the Company has the right to renew for a total of 5 years. A second lease began on March 31, 2023, for an additional 167.6 acres at a cost of $24,721 every 6 months that the Company also can continue for up to 5 years. Since those leases can be terminated at will, they are not included in the ROU or lease liability on the Company’s balance sheet.

 

Rent expense for the six months ending June 30, 2023, and 2022, were $108,893 and $64,724, respectively.

 

The Company recognized the following related to leases in its Consolidated Balance Sheet:

 

PERIOD ENDED 

June 30, 2023

  

December 31, 2022

 
Right of Use Lease Liabilities          
Current portion   99,626    95,172 
Long-term portion   34,909    85,983 
TOTAL   134,535    181,155 

 

As of June 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:

 

YEAR ENDED 

MINIMUM

DUE

 
2023   48,552 
2024   85,983 
2025   0 
      
TOTAL  $134,535 

 

16

 

 

NOTE 9 – RELATED PARTY TRANSACTIONS

 

Related Party Transactions

 

The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

  1) Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 6.
  2) A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they continued to receive less than full salaries.

 

The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.

 

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:

 

From July 1, 2023, to the date of this filing, the Company received an SBIR Phase I grant from the Department of Energy valued at $206,500.

 

From July 1, 2023, to the date of this filing, the Company issued 0 shares for services.

 

From July 1, 2023, to the date of this filing, 125,000 options expired.

 

From July 1, 2023, to the date of this filing, 1,200,000 unvested options were issued at an exercise price of 16 cents per share and expiration dates of 5 and 10 years. Using the Black-Scholes option pricing model, they were valued at $160,497.

 

From July 1, 2023, to the date of this filing, the Company issued 500,000 shares in a private placement for proceeds of $75,000.

 

From July 1, 2023, to the date of this filing, the Company issued convertible notes to related parties for $25,000. Instead of interest, it accrues warrants at the rate of 50,000 per year. Those warrants were valued at $5,812 using the Black Scholes option pricing model.

 

17

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 

The following discussion should be read in conjunction with the Company’s audited financial statements and the notes thereto.

 

Forward-Looking Statements

 

This quarterly report contains forward-looking statements and information relating to the Company that are based on the beliefs of its management as well as assumptions made by, and information currently available to, its management. When used in this report, the words “believe,” “anticipate,” “expect,” “estimate,” “intend”, “plan” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements reflect management’s current view of the Company concerning future events and are subject to certain risks, uncertainties and assumptions, including among many others: a general economic downturn; a downturn in the securities markets; federal or state laws or regulations having an adverse effect on proposed transactions that the Company desires to effect; Securities and Exchange Commission regulations which affect trading in the securities of “penny stocks”; and other risks and uncertainties. Should any of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report as anticipated, estimated or expected. The accompanying information contained in this registration statement, including, without limitation, the information set forth under the heading “Management’s Discussion and Analysis and Plan of Operation — Risk Factors” identifies important additional factors that could materially adversely affect actual results and performance. You are urged to carefully consider these factors. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the foregoing cautionary statement.

 

Business Overview

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.

 

In early 2018, the Company’s chief executive officer (“CEO”) Ben Slager invented a new technology system referred to as Cellulose-to-Sugar or CTS, and the Company filed a process patent application for this technology. Mr. Slager has since further developed the system with laboratory personnel. The CTS patent was awarded in 2021 in the United States (U.S. Patent No. 10,994,255) and also in El Salvador. The Company also filed this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, Japan, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. In addition to this patent, the Company has received one additional patent (for which it has also applied for in all the above-mentioned jurisdictions). Further, the company has filed for 4 other patents which are currently pending.

 

Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for breaking down cellulosic material for conversion into biofuels. CTS can break down any cellulosic material – including grasses and agricultural waste. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.

 

CTS is environmentally friendly in that it recycles the water and catalyst, and it has a low carbon footprint: the amount of added atmospheric carbon created by burning the biofuels produced by the CTS system was absorbed by the plant-based feedstock while growing and is merely released back into the atmosphere. No extra CO2 is released into the atmosphere when our biofuels are burned. This is to be distinguished from fossil fuels because new CO2 is released when fossil fuels are burned.

 

18

 

 

At a commercial scale, our management expects to be able to produce ethanol at a lower cost per gallon than existing commercial corn or cellulosic ethanol producers due to the fact that the CTS process is robust, uncomplicated and efficient, and is expected to use low-cost feedstocks and have a potentially high value by-product, lignin. We believe a significant difference between CTS ethanol and corn ethanol is the wide range of abundantly available feedstocks that CTS can process compared to just corn as the feedstock. The CTS feedstocks are nonfood and have much lower costs than corn. In addition, while in corn ethanol only the corn kernels are used, CTS uses the whole plant or its waste products, meaning it could obtain much higher yields per acre. The Company also expects to potentially receive a highly valued D3 RIN for each gallon of ethanol it produces.

 

The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.

 

In 2022, the Company partnered with K.R. Komarek to build its CTS machines going forward. In 2023, the Company completed the build-out of a pilot plant based on a modified Komarek machine and is in the process of further testing and optimizing the plant. Komarek is an industry leading manufacturing company that builds briquetting machines and compaction/granulation systems with throughput capacities up to 50 tons per hour.

 

The Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF). The license agreement with Vertimass is the subject to a confidentiality agreement between the parties.

 

Plan of Operation

 

The Company will prioritize building an SAF facility to generate revenue sooner. First, the Company intends to build a commercial scale ethanol to SAF facility and subsequently build commercial CTS and ethanol facilities on the front-end of that to produce cellulosic SAF and generate the large D7 RIN and other government credits.

 

Commencing commercial production will require project financing. The project financing is planned to initially be for setting up a 10 million gallon per year production facility for converting ethanol into jet fuel using the Vertimass Process that the Company has licensed. Parallel to that, the Company plans to build a semicommercial CTS demonstration plant that integrates a larger CTS system into the pre-processing and post-processing elements of the plant. The goal of the semi-commercial plant is to finalize design and operational parameters at this volume level and to provide operating cost estimates of a full commercial volume system. Due to its mechanical nature and modularity, we anticipate that one plant would have multiple modular CTS systems.

 

After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the technology or forming joint ventures with foreign domestic partners to build plants.

 

19

 

 

The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as the feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic suppliers, we anticipate that our profitability will be more consistent.

 

Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.

 

The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (EPA), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.02 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.

 

Section 45Z of the Inflation Reduction Act passed on August 16, 2022, offers a Clean Fuel Production Credit (CFPC) per gallon of transportation fuel produced with a base amount of 20 cents per gallon or $1 per gallon for a qualified facility that was built while paying at least prevailing wages and which met apprenticeship requirements. For sustainable aviation fuel, those figures are 35 cents and $1.75 per gallon respectively. The Company plans to apply for CFPC credits when it begins building its commercial facilities. The CFPC currently does not apply to transportation fuel sold after December 31, 2027.

 

A Low Carbon Fuel Standard Credit (LCFS) is offered by various states (primarily California) for any amount of reduced CO2 in the production lifecycle of transportation fuels as compared to the amount of CO2 emitted in the production lifecycle of fossil fuels. The production lifecycle includes transportation costs to the point of use. California is currently offering around $72.50 per metric ton of CO2 reduction. When it is closer to commercial production, the Company plans to analyze the cost effectiveness of applying for these LCFS credits to determine in which state it could earn the most credits.

 

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has not generated any material revenues from its business.

 

20

 

 

Capital Formation

 

From January 1, 2023, through the date of filing, the Company issued an aggregate of 174,194 shares of its common stock for services valued at $29,300.

 

From January 1, 2023, through the date of filing, the Company issued an aggregate of 5,018,332 shares of its common stock for capital of $752,772.

 

From January 1, 2023, through the date of filing, 5,950,148 warrants were exercised for $97,250.

 

From January 1, 2023, through the date of filing, the Company issued unvested options to its managers and employees to purchase 17,150,000 shares of its common stock for a period of ten years at the exercise price of 16 to 20 cents per share. Using a Black-Scholes asset-pricing model, these agreements were valued at $2,835,613. None of those have vested. 1,000,000 vested options were issued at exercise prices between 16 and 19 cents. 3,385,000 previously issued options have vested. Using a Black-Scholes option pricing model, these vested options have a valuation of $637,028.

 

From January 1, 2023, through the date of filing, 7,050,000 options expired or were cancelled and 2,067,999 warrants expired.

 

Going Concern

 

The Company has incurred losses since inception, has a working capital deficiency, and may be unable to raise further capital. At June 30, 2023, the Company had a working capital deficit of $1,155,030 and had incurred accumulated losses of $54,999,875 since its inception. The Company expects to incur significant additional losses in connection with its continued start-up activities. As a result, there is substantial doubt about the Company’s ability to continue as a going concern based upon recurring operating losses and its need to obtain additional financing to sustain operations. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses.

 

Results of Operations

 

Comparison of the three and six month period ended June 30, 2023 (unaudited) to June 30, 2022

 

For the three and six months ended June 30, 2023, the Company recognized $0 in revenue as opposed to $0 in 2022.

 

For the three months ended June 30, 2023, the Company’s general and administrative expenses increased by $113,817 to $355,324 from $241,507 in 2022. This increase is primarily the result of $84,684 in equity-based compensation in 2023 versus $0 in 2022.

 

For the six months ended June 30, 2023, the Company’s general and administrative expenses decreased by $319,402 to $725,169 from $1,044,571 2022. This decrease is primarily the result of $169,382 in equity based compensation versus $495,532 in 2022.

 

Interest expense increased in the quarter ended June 30, 2023 by $28,857 to $36,161 from $7,304 in 2022. Interest expense increased in the six months ended June 30, 2023 by $30,430 to $45,475 from $15,045 in 2022.

 

For the six months ended June 30, 2023 the Company recorded non-cash impairments of assets of $369 as compared to $40,099 in 2022. This was the result of disposing and/or selling of laboratory assets no longer in use in each year.

 

Research and development (R&D) costs for the quarter ended June 30, 2023 were $762,714, an increase of $326,234 from $436,480 in 2022. The increase in R&D expenses is primarily the result of bonuses and equity based compensation of $422,703 versus $141,106 in 2022.

 

21

 

 

Research and development (R&D) costs for the six months ended June 30, 2023 were $1,447,276, a decrease of $219,357 from $1,666,632 in 2022. The decrease in R&D expenses is primarily the result of a decrease in equity based compensation to $467,646 from $919,851 in 2022 due to the vesting of more options in 2022.

 

Liquidity and Capital Resources

 

Liquidity

 

As of June 30, 2023, the Company had $61,677 in cash, and total stockholders’ equity on June 30, 2023, was negative $3,091,220. As of December 31, 2022, the Company had $211,901 in cash, and total stockholders’ equity at December 31, 2022, was negative $2,356,917. Total debt, including advances, accounts payable and other notes payable at June 30, 2023, together with interest payable thereon and contingent liabilities, was $4,250,866 an increase of $788,030 from December 31, 2022, where it stood at $3,462,836. This increase is primarily attributable to new convertible notes due to a related parties. $1,820,630 of the remaining debt has been renegotiated to be payable out of future revenue and $917,502 out of future profits and otherwise does not come due.

 

During the six months ended June 30, 2023, the Company’s net cash used in operating activities decreased by $25,397 to $1,180,587 from $1,205,985 in the six months ending June 30, 2022.

 

During the six months ended June 30, 2023, the Company’s investing activities used $294,659 in cash, as compared to $20,673 in the first half of 2022. This can be primarily attributed to capitalizing $12,621 in patent costs and $282,038 used to purchase machinery and equipment, as compared to $18,272 in patent costs and $2,400 in net purchases of equipment in the first half of 2022.

 

During the six months ended June 30, 2023, the Company generated an aggregate of $1,325,022 through its financing activities versus $690,900 in the six months ended June 30, 2022, which is an increase of $634,122. This increase from the prior year can primarily be attributed to the issuance of $550,000 in convertible notes to related parties in 2023.

 

Capital Resources

 

At this time, the Company has limited liquidity and capital resources. To continue funding its operations, the Company will need to generate revenue or obtain additional financing for current and future operations. The Company anticipates needing around $15 million to build and optimize a semi-commercial scale CTS system, and then will seek project financing for a commercial system. There is no guarantee that we will achieve all of the additional funding that is needed.

 

As of the date of this filing, the Company has raised $800,022 in 2023, through the issuance of shares and the exercise of warrants, plus $15,863,601 raised previously, in addition to capital raised through debt or convertible notes including $575,000 raised through convertible notes in 2023. However, there is no guarantee that the company will be able to raise any additional capital on terms acceptable to the Company.

 

The inability to obtain this funding either in the near term and/or longer term will materially affect the ability of the Company to implement its business plan of operations and jeopardize the viability of the Company. In that case, the Company may need to reevaluate and revise its operations.

 

Equity

 

As of June 30, 2023, shareholders’ equity was negative $3,091,220.

 

There were 300,584,297 shares of common stock issued and outstanding as of June 30, 2023.

 

There were no preferred shares outstanding.

 

The Company has paid no dividends.

 

22

 

 

Critical Accounting Policies

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Seasonality

 

The Company’s operating results are not affected by seasonality.

 

Inflation

 

The Company’s business and operating results are not affected in any material way by inflation.

 

Contractual Obligations

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

As required by Rule 13a-15(e) of the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of December 31, 2021. Based upon, and as of the date of this evaluation, our chief executive officer and chief financial officer determined that our disclosure controls and procedures were sufficient.

 

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of December 31, 2021, that occurred during our first fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

23

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. As of the date of filing, there are no material claims or suits whose outcomes could have a material effect on the Company’s financial statements.

 

ITEM 1A. RISK FACTORS.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

 

Below is a list of securities sold by the Company from January 1, 2023, through the date of filing which were not registered under the Securities Act.

 

Entity   Date of Investment  

Title of

Security

  Amount of Securities Sold     Consideration
Raymond Leon   01/03/23   Common Stock     200,000     Purchased @ $0.15 per share
James Cherwin   01/30/23   Common Stock     100,000     Purchased @ $0.15 per share
Edmund Burke   01/30/23   Common Stock     4,450,148     Exercise of Warrants
Edmund Burke   01/31/23   Common Stock     1,000,000     Exercise of Warrants
NWBB, Inc   02/06/23   Common Stock     40,000     Professional Services
Ron Smith   02/06/23   Common Stock     166,666     Purchased @ $0.15 per share
Mark Monahan   02/17/23   Common Stock     333,333     Purchased @ $0.15 per share
Michael Fidler   02/17/23   Common Stock     200,000     Purchased @ $0.15 per share
Joseph Corry   02/17/23   Common Stock     100,000     Purchased @ $0.15 per share
William Newman   02/21/23   Common Stock     100,000     Purchased @ $0.15 per share
Johnny Anastasiades   03/01/23   Common Stock     135,000     Purchased @ $0.15 per share
Jozef Kneppers   03/06/23   Common Stock     1,333,333     Purchased @ $0.15 per share
James Dupre & Michelle Dupre   03/06/23   Common Stock     150,000     Purchased @ $0.15 per share
Randall Brodsky   03/07/23   Common Stock     400,000     Purchased @ $0.15 per share
Tamara Chapman Revocable Trust   03/08/23   Common Stock     333,333     Purchased @ $0.15 per share
John Comrie   03/08/23   Common Stock     333,333     Purchased @ $0.15 per share
William Fitzpatrick   03/24/23   Common Stock     100,000     Professional Services
Neil Hendry   04/05/23   Common Stock     66,667     Purchased @ $0.15 per share
NWBB, Inc.   04/10/23   Common Stock     34,194     Professional Services
Clay Taylor   04/11/23   Common Stock     400,000     Purchased @ $0.15 per share
Kophyo Win   05/05/23   Common Stock     166,667     Purchased @ $0.15 per share
Patrick Simms   05/15/23   Common Stock     500,000     Exercise of Warrants
Mark Monahan   07/19/23   Common Stock     166,667     Purchased @ $0.15 per share
Anthony Santelli   07/26/23   Common Stock     333,333     Purchased @ $0.15 per share

 

The securities issued in the above-mentioned transactions were issued in connection with private placements exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended, pursuant to the terms of Section 4(a)(2) of that Act and Rules 504 and 506 of Regulation D.

 

24

 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

The exhibits listed below are filed as part of or incorporated by reference in this report.

 

Exhibit No.   Identification of Exhibit
     
2.1   Chapter 11 Plan of Reorganization (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
2.2   Chapter 11 Disclosure Statement (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
3.1   Articles of Incorporation (incorporated by reference to the Company’s S-1 filed May 23, 2021)
     
3.2   Certificate of Amendment to Articles of Incorporation filed November 19, 2014 (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
3.3   Certificate of Amendment to Articles of Incorporation filed June 17, 2016 (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
3.4   Certificate of Amendment to Articles of Incorporation filed July 26, 2021 (incorporated by reference to the Company’s 8-K filed on July 30, 2021)
     
3.5   Bylaws (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
10.1   Lease Agreement (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
10.2   Employment Agreement, dated June 1, 2020, between the Company and Ben Slager (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
10.3   Employment Agreement, dated June 1, 2020, between the Company and Anthony Santelli (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021
     
10.4   2021 Employee, Director Stock Plan (incorporated by reference to definitive 14C filed with the SEC on June 24, 2021)
     
31.1.   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1   Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2   Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

25

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Blue Biofuels, Inc.
  (Registrant)
   
  By /s/ Benjamin Slager
    Benjamin Slager
    Chief Executive Officer, (Principal Executive Officer)
     
  Date  August 7, 2023
     
  By /s/ Anthony Santelli
    Anthony Santelli
    Chief Financial Officer (Principal Financial and Accounting Officer)
     
  Date  August 7, 2023

 

26

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, Benjamin Slager, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Blue Biofuels, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
       
    a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
       
    a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2023

 

/s/ Benjamin Slager  
Benjamin Slager  

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Anthony Santelli, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Blue Biofuels, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
       
    a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
       
    a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2023

 

/s/ Anthony Santelli  
Anthony Santelli  

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Benjamin Slager, the Chief Executive Officer of Blue Biofuels, Inc (the “Company”), DOES HEREBY CERTIFY that:

 

1. The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

IN WITNESS WHEREOF, the undersigned has executed this statement this 7th day of August, 2023.

 

  /s/ Benjamin Slager
  Benjamin Slager
 

Chief Executive Officer

(Principal Executive Officer)

 

A signed original of this written statement required by Section 906 has been provided to Blue Biofuels, Inc. and will be retained by Blue Biofuels, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Anthony Santelli, the Chief Financial Officer of Blue Biofuels, Inc. (the “Company”), DOES HEREBY CERTIFY that:

 

1. The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

IN WITNESS WHEREOF, the undersigned has executed this statement this 7th day of August, 2023.

 

  /s/ Anthony Santelli
  Anthony Santelli
 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

A signed original of this written statement required by Section 906 has been provided to Blue Biofuels, Inc. and will be retained by Blue Biofuels, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

EX-101.SCH 6 biof-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statement of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - PATENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ORGANIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 biof-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 biof-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 biof-20230630_lab.xml XBRL LABEL FILE Related Party Transaction [Axis] Nonrelated Party [Member] Related Party [Member] Equity Components [Axis] Common Stock [Member] Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Award Date [Axis] Issuance Date 2/10/23 [Member] Warrant [Member] Issuance Date 2/14/23 [Member] Issuance Date 3/1/23 [Member] Issuance Date 3/31/2023 [Member] Issuance Date 4/5/23 [Member] Issuance Date 4/11/23 [Member] Issuance Date 4/26/23 [Member] Issuance Date 6/5/23 [Member] Issuance Date 7/13/23 [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Long-Lived Tangible Asset [Axis] Building Improvements [Member] Machinery and Equipment [Member] Furniture and Fixtures [Member] Computer Equipment [Member] Pilot Plant [Member] Machinery [Member] Office and Laboratory Space [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Product and Service [Axis] SBIR Phase I Grant [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] ASSETS Current assets Cash and cash equivalents Prepaid expenses TOTAL CURRENT ASSETS Other assets Property and equipment, net of accumulated depreciation and amortization of $184,283 and $127,178 at June 30, 2023 and December 31,2022, respectively Security deposits Right of Use Assets, net of accumulated amortization Patents TOTAL OTHER ASSETS TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities Accounts payable Deferred wages and director’s fees - Related party Lease Liability - Current Chapter 11 Settlement Convertible Notes Payable — Related Party Interest Payable - Related Party TOTAL CURRENT LIABILITIES Long term liabilities Right of Use Lease Liability, net of current portion Notes Payable — Related Party Notes Payable — Other TOTAL LONG TERM LIABILITIES TOTAL LIABILITIES STOCKHOLDERS’ EQUITY (DEFICIT) Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding Common stock; $0.001 par value; 1,000,000,000 shares authorized; 300,584,297 issued and outstanding at June 30, 2023, and 289,941,623 shares issued and outstanding at December 31, 2022. Additional paid-in capital Accumulated deficit Total stockholders’ equity (deficit) TOTAL EQUITY (DEFICIT) TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Statement of Financial Position [Abstract] Accumulated depreciation and amortization on property and equipment Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares outstanding Common stock, shares issued Revenues Operating expense: General and administrative Research & Development Loss on disposal of assets Total operating expenses Loss from operations: Other (income) expense: Interest expense - related party Interest expense - other Total other (income) expense Income (Loss) before provisions for income taxes Provisions for income taxes Net Income / (Loss): Net income (loss) per share Net income (loss) per share, fully diluted Weighted average common shares outstanding Basic Fully Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Issuance of common stock for services Issuance of common stock for services, shares Issuance of common stock and warrants for cash through PPM Issuance of common stock and warrants for cash through PPM, shares Warrants exercised Warrants exercised, shares Vesting of options under the employee, director plan Net Income (Loss) Issuance of 314,000 warrants for services Employee stock options exercised Employee stock options exercised, shares Balance Balance, shares Statement of Stockholders' Equity [Abstract] Vesting of options previously issued under employee director plan Warrants issued for services Statement of Cash Flows [Abstract] Cash flows from operating activities Reconciliation of net loss to net cash used in operating activities Depreciation and amortization Stock based compensation for services Net Issuance of options and warrants for services Extinguishment of Debt Loss on Disposal of assets Changes in operating assets and liabilities Prepaid expenses Accrued interest - related party Accounts payable and accrued liabilities Right of use lease Net cash used in operating activities Cash flows from investing activities Net Purchase of property and equipment Security deposits Patent Costs Net cash from (used in) investing activities Cash flows from financing activities Proceeds from exercise of warrants and options Net Proceeds from the issuance of Convertible Notes Net proceeds from issuance of common stock Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalent at beginning of the period Cash and cash equivalent at end of the period Supplemental disclosure of cash flow information Cash paid during the period for Interest Taxes Supplemental schedule of non-cash activities Cashless conversion of warrants/options Conversion of convertible debenture to common stock Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION GOING CONCERN Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] PATENTS Debt Disclosure [Abstract] DEBT Equity [Abstract] STOCKHOLDERS’ EQUITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Principles of Consolidation Use of Estimates Cash and Cash Equivalents Stock Compensation Stock-based Compensation Valuation Methodology Property and Equipment Patent Capitalization Research and Development Revenue Recognition Common Stock Purchase Warrants and Other Derivative Financial Instruments Impairment of Long-Lived Assets Income Taxes Profit (Loss) per Common Share: Fair Value Measurements Recent Accounting Pronouncements SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF NOTES PAYABLE SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Renewable fuel description Accumulated losses Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Risk-free interest rate Expected life Expected dividends Expected volatility BIOF common stock fair value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment, estimated useful life Research and development expenses Property and Equipment, gross Estimated Useful Lives Less Accumulated Depreciation Property and Equipment Depreciation Purchase of machinery Disposal of machinery Purchase value Accumulated depreciation Loss on disposal of assets Finite-Lived Patents, Gross Short Term Convertible Note – Related Party Short Term Chapter 11 Settlement Long Term Notes Payable after capital investment received Long Term Notes Payable from future revenue — Related Party Long Term Notes Payable from future revenue — Other Long Term Note Payable from future profits — Related Party Long Term Note Payable from future profits — Other TOTAL NOTES Capital units, authorized Preferred stock, shares Issued Number of shares issued for services, shares Number of shares issued for services, value Warrants issued for services, value Warrants exercised share, shares Number of warrants expired Unvested options expired Number of stock options vested, shares Number of stock options vested, value Number of shares unvested Options issued and unvested value Current portion Long-term portion TOTAL 2023 2024 2025 TOTAL Lease extension period Annual rent Percentage of increase in rent per year Lease expense Operating costs Acres Lease cost Lease renewal term Rent expense Subsequent Event [Table] Subsequent Event [Line Items] SBIR phase I grants Shares issued for services Stock options expired Number of unvested shares issued Exercise price Expiration date Number of unvested shares issued, value Number of shares issued for private placement Proceeds from issuance of private placement Convertible note Conversion of convertible note into shares Warrants valued Stockholders Equity Deficit. Increase decrease in right of use lease. Payments for patent costs. Cashless conversion of warrants. Conversion of convertible debenture to common stock. Issuance of common stock and warrants for cash through ppm. Warrants exercised. Issuance of common stock and warrants for cash through Ppm shares. Warrants exercised share. Warrants issued during period value issued for services. Warrants issued during period shares issued for services. Stock issued during period value stock options exercised1. Stock issued during period shares stock options exercised. Renewable Fuel Description. Stockbased Compensation Valuation Methodology [Policy Text Block] Issuance Date February Ten Two Thousand Twenty Three [Member] Issuance Date February Fourteen Two Thousand Twenty Three [Member] Issuance Date March One Two Thousand Twenty Three [Member] Issuance Date April Five Two Thousand Twenty Three [Member] Issuance Date April Eleven Two Thousand Twenty Three [Member] Issuance Date March Thirty First Two Thousand Twenty Three [Member] Issuance Date April Twenty Six Two Thousand Twenty Three [Member] Issuance Date June Five Two Thousand Twenty Three [Member] Issuance Date July Thirteen Two Thousand Twenty Three [Member] Common Stock Purchase Warrants And Other Derivative Financia lInstruments [Policy Text Block]. Pilot Plant [Member] Machinery [Member] Long term notes payable from future revenue related party. Long Term Notes Payable From Future Revenue Other. Long term note payable from future profits related party. Long term note payable from future profits other. Long term notes payable after capital investment received. Sharebased compensation arrangement by sharebased payment award options issued and unvested in period fair value. Office and Laboratory Space [Member] Annual rent. Percentage of increase in rent per year. Lease renewal term. Share based compensation arrangement by share based payment award options non vested number of shares value. Warrants issued for service. SBIR Phase I Grant [Member] Share based compensation arrangement by share based payment award options issued in period weighted average exercise price. Grants received. Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities, Noncurrent Liabilities Equity, Attributable to Parent Stockholders Equity Deficit Liabilities and Equity Gain (Loss) on Disposition of Assets Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Gain (Loss) on Extinguishment of Debt Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments for Other Deposits PaymentsForPatentCosts Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Notes Payable Operating Lease, Liability Lessee, Operating Lease, Liability, to be Paid EX-101.PRE 10 biof-20230630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover - shares
6 Months Ended
Jun. 30, 2023
Aug. 05, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2023  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 000-54942  
Entity Registrant Name BLUE BIOFUELS, INC.  
Entity Central Index Key 0001549145  
Entity Tax Identification Number 45-4944960  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 3710 Buckeye Street  
Entity Address, Address Line Two Suite 120  
Entity Address, City or Town Palm Beach Gardens  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33410  
City Area Code (888)  
Local Phone Number 607-3555  
Trading Symbol BIOF  
Title of 12(g) Security Common Stock par value $0.001  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   301,084,297
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 61,677 $ 211,901
Prepaid expenses 61,118 43,119
TOTAL CURRENT ASSETS 122,795 255,020
Other assets    
Property and equipment, net of accumulated depreciation and amortization of $184,283 and $127,178 at June 30, 2023 and December 31,2022, respectively 642,100 420,115
Security deposits 30,276 30,276
Right of Use Assets, net of accumulated amortization 129,745 178,399
Patents 234,730 222,109
TOTAL OTHER ASSETS 1,036,851 850,899
TOTAL ASSETS 1,159,646 1,105,919
Current liabilities    
Lease Liability - Current 99,626 95,172
Chapter 11 Settlement 50,000
Interest Payable - Related Party 102,718 76,138
TOTAL CURRENT LIABILITIES 1,277,825 638,721
Long term liabilities    
Right of Use Lease Liability, net of current portion 34,909 85,983
Notes Payable — Other 216,570 216,570
TOTAL LONG TERM LIABILITIES 2,973,041 2,824,115
TOTAL LIABILITIES 4,250,866 3,462,836
STOCKHOLDERS’ EQUITY (DEFICIT)    
Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding
Common stock; $0.001 par value; 1,000,000,000 shares authorized; 300,584,297 issued and outstanding at June 30, 2023, and 289,941,623 shares issued and outstanding at December 31, 2022. 300,584 289,942
Additional paid-in capital 51,608,070 50,134,727
Accumulated deficit (54,999,875) (52,781,586)
Total stockholders’ equity (deficit) (3,091,221) (2,356,917)
TOTAL EQUITY (DEFICIT) (3,091,221) (2,356,917)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 1,159,646 1,105,919
Nonrelated Party [Member]    
Current liabilities    
Accounts payable 14,735 37,135
Related Party [Member]    
Current liabilities    
Accounts payable 72,670 72,670
Deferred wages and director’s fees - Related party 638,076 307,606
Convertible Notes Payable — Related Party 350,000
Long term liabilities    
Notes Payable — Related Party $ 2,721,562 $ 2,521,562
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Accumulated depreciation and amortization on property and equipment $ 184,283 $ 127,178
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares outstanding 300,584,297 289,941,623
Common stock, shares issued 300,584,297 289,941,623
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statement of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Related Party Transaction [Line Items]        
Revenues
Operating expense:        
General and administrative 355,324 241,507 725,169 1,044,571
Research & Development 762,714 436,480 1,447,276 1,666,632
Loss on disposal of assets 40,099 369 40,099
Total operating expenses 1,118,038 718,086 2,172,813 2,751,302
Loss from operations: (1,118,038) (718,086) (2,172,813) (2,751,302)
Other (income) expense:        
Interest expense - other 2,378 592 4,981 1,621
Total other (income) expense 36,161 7,304 45,475 15,045
Income (Loss) before provisions for income taxes (1,154,199) (725,390) (2,218,288) (2,766,347)
Provisions for income taxes    
Net Income / (Loss): $ (1,154,199) $ (725,390) $ (2,218,288) $ (2,766,347)
Net income (loss) per share $ (0.004) $ (0.003) $ (0.007) $ (0.010)
Net income (loss) per share, fully diluted $ (0.003) $ (0.002) $ (0.006) $ (0.008)
Weighted average common shares outstanding        
Basic 297,635,565 275,876,745 297,635,565 275,876,745
Fully Diluted 351,822,695 331,481,205 351,822,695 331,481,205
Related Party [Member]        
Other (income) expense:        
Interest expense - related party $ 33,783 $ 6,712 $ 40,495 $ 13,424
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 274,004 $ 47,151,353 $ (48,821,403) $ (1,396,046)
Balance, shares at Dec. 31, 2021 274,003,883        
Issuance of common stock for services $ 448 70,852 71,300
Issuance of common stock for services, shares 447,781        
Vesting of options under the employee, director plan   1,316,277 1,316,277
Net Income (Loss)       (2,040,957) (2,040,957)
Employee stock options exercised $ 150 7,350 7,500
Employee stock options exercised, shares 150,000        
Balance at Mar. 31, 2022 $ 274,602 48,545,832 (50,862,360) (2,041,926)
Balance, shares at Mar. 31, 2022 274,601,664        
Balance at Dec. 31, 2021 $ 274,004 47,151,353 (48,821,403) (1,396,046)
Balance, shares at Dec. 31, 2021 274,003,883        
Net Income (Loss)         (2,766,347)
Balance at Jun. 30, 2022 $ 279,380 49,339,710 (51,587,750) (1,968,660)
Balance, shares at Jun. 30, 2022 279,380,263        
Balance at Mar. 31, 2022 $ 274,602 48,545,832 (50,862,360) (2,041,926)
Balance, shares at Mar. 31, 2022 274,601,664        
Issuance of common stock for services $ 79 16,071 16,150
Issuance of common stock for services, shares 78,600        
Issuance of common stock and warrants for cash through PPM $ 4,500 670,500 675,000
Issuance of common stock and warrants for cash through PPM, shares 4,499,999        
Vesting of options under the employee, director plan   99,106 99,106
Net Income (Loss)       (725,390) (725,390)
Employee stock options exercised $ 200 8,200 8,400
Employee stock options exercised, shares 200,000        
Balance at Jun. 30, 2022 $ 279,380 49,339,710 (51,587,750) (1,968,660)
Balance, shares at Jun. 30, 2022 279,380,263        
Balance at Dec. 31, 2022 $ 289,942 50,134,727 (52,781,586) (2,356,917)
Balance, shares at Dec. 31, 2022 289,941,623        
Issuance of common stock for services $ 140 23,860 24,000
Issuance of common stock for services, shares 140,000        
Issuance of common stock and warrants for cash through PPM $ 3,885 578,865 582,750
Issuance of common stock and warrants for cash through PPM, shares 3,884,998        
Warrants exercised $ 5,450 66,800 72,250
Warrants exercised, shares 5,450,148        
Vesting of options under the employee, director plan   391,297 391,297
Net Income (Loss)       (1,064,090) (1,064,090)
Balance at Mar. 31, 2023 $ 299,417 51,195,549 (53,845,676) (2,350,710)
Balance, shares at Mar. 31, 2023 299,416,769        
Balance at Dec. 31, 2022 $ 289,942 50,134,727 (52,781,586) (2,356,917)
Balance, shares at Dec. 31, 2022 289,941,623        
Issuance of common stock for services         $ 29,300
Issuance of common stock for services, shares         174,191
Issuance of common stock and warrants for cash through PPM         $ 677,771
Issuance of common stock and warrants for cash through PPM, shares         4,518,332
Warrants exercised         $ 97,250
Warrants exercised, shares         5,950,148
Net Income (Loss)         $ (2,218,288)
Balance at Jun. 30, 2023 $ 300,584 51,608,069 (54,999,875) (3,091,221)
Balance, shares at Jun. 30, 2023 300,584,297        
Balance at Mar. 31, 2023 $ 299,417 51,195,549 (53,845,676) (2,350,710)
Balance, shares at Mar. 31, 2023 299,416,769        
Issuance of common stock for services $ 34 5,266 5,300
Issuance of common stock for services, shares 34,194        
Issuance of common stock and warrants for cash through PPM $ 633 94,389 95,022
Issuance of common stock and warrants for cash through PPM, shares 633,334        
Warrants exercised $ 500 24,500 25,000
Warrants exercised, shares 500,000        
Vesting of options under the employee, director plan   245,732 245,732
Net Income (Loss)       (1,154,199) (1,154,199)
Issuance of 314,000 warrants for services   42,634 42,634
Balance at Jun. 30, 2023 $ 300,584 $ 51,608,069 $ (54,999,875) $ (3,091,221)
Balance, shares at Jun. 30, 2023 300,584,297        
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Statement of Stockholders' Equity [Abstract]          
Vesting of options previously issued under employee director plan 2,000,000 2,385,000 800,000 10,560,000 4,385,000
Warrants issued for services 314,000       314,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities    
Net Income (Loss) $ (2,218,288) $ (2,766,347)
Reconciliation of net loss to net cash used in operating activities    
Depreciation and amortization 59,684 68,123
Stock based compensation for services 29,300 87,450
Net Issuance of options and warrants for services 679,662 1,415,383
Extinguishment of Debt (50,000)  
Loss on Disposal of assets 369 40,099
Changes in operating assets and liabilities    
Prepaid expenses (18,000) (66,896)
Accrued interest - related party 26,581 13,424
Accounts payable and accrued liabilities 308,070 45,753
Right of use lease 2,035 (42,974)
Net cash used in operating activities (1,180,587) (1,205,985)
Cash flows from investing activities    
Net Purchase of property and equipment (282,038) (2,400)
Security deposits
Patent Costs (12,621) (18,273)
Net cash from (used in) investing activities (294,659) (20,673)
Cash flows from financing activities    
Proceeds from exercise of warrants and options 97,250 15,900
Net Proceeds from the issuance of Convertible Notes 550,000  
Net proceeds from issuance of common stock 677,772 675,000
Net cash provided by financing activities 1,325,022 690,900
Net increase (decrease) in cash and cash equivalents (150,224) (535,758)
Cash and cash equivalent at beginning of the period 211,901 1,164,664
Cash and cash equivalent at end of the period 61,677 628,906
Cash paid during the period for    
Interest
Taxes
Supplemental schedule of non-cash activities    
Cashless conversion of warrants/options
Conversion of convertible debenture to common stock
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION

NOTE 1 – ORGANIZATION

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.

 

In early 2018, the Company’s chief executive officer (“CEO”) Ben Slager invented a new technology system referred to as Cellulose-to-Sugar or CTS, and the Company filed a process patent application for this technology. Mr. Slager has since further developed the system with laboratory personnel. The CTS patent was awarded in 2021 in the United States (U.S. Patent No. 10,994,255) and also in El Salvador. The Company also filed this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, Japan, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. In addition to this patent, the Company has received one additional patent (for which it has also applied for in all the above-mentioned jurisdictions). Further, the company has filed for 4 other patents which are currently pending.

 

Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for breaking down cellulosic material for conversion into biofuels. CTS can break down any cellulosic material – including grasses and agricultural waste. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.

 

CTS is environmentally friendly in that it recycles the water and catalyst, and it has a low carbon footprint: the amount of added atmospheric carbon created by burning the biofuels produced by the CTS system was absorbed by the plant-based feedstock while growing and is merely released back into the atmosphere. No extra CO2 is released into the atmosphere when our biofuels are burned. This is to be distinguished from fossil fuels because new CO2 is released when fossil fuels are burned.

 

At a commercial scale, our management expects to be able to produce ethanol at a lower cost per gallon than existing commercial corn or cellulosic ethanol producers due to the fact that the CTS process is robust, uncomplicated and efficient, and is expected to use low-cost feedstocks and have a potentially high value by-product, lignin. We believe a significant difference between CTS ethanol and corn ethanol is the wide range of abundantly available feedstocks that CTS can process compared to just corn as the feedstock. The CTS feedstocks are nonfood and have much lower costs than corn. In addition, while in corn ethanol only the corn kernels are used, CTS uses the whole plant or its waste products, meaning it could obtain much higher yields per acre. The Company also expects to potentially receive a highly valued D3 RIN for each gallon of ethanol it produces.

 

The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.

 

In 2022, the Company partnered with K.R. Komarek to build its CTS machines going forward. In 2023, the Company completed the build-out of a pilot plant based on a modified Komarek machine and is in the process of further testing and optimizing the plant. Komarek is an industry leading manufacturing company that builds briquetting machines and compaction/granulation systems with throughput capacities up to 50 tons per hour.

 

The Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF). The license agreement with Vertimass is the subject to a confidentiality agreement between the parties.

 

 

Plan of Operation

 

The Company will prioritize building an SAF facility to generate revenue sooner. First, the Company intends to build a commercial scale ethanol to SAF facility and subsequently build commercial CTS and ethanol facilities on the front-end of that to produce cellulosic SAF and generate the large D7 RIN and other government credits.

 

Commencing commercial production will require project financing. The project financing is planned to initially be for setting up a 10 million gallon per year production facility for converting ethanol into jet fuel using the Vertimass Process that the Company has licensed. Parallel to that, the Company plans to build a semicommercial CTS demonstration plant that integrates a larger CTS system into the pre-processing and post-processing elements of the plant. The goal of the semi-commercial plant is to finalize design and operational parameters at this volume level and to provide operating cost estimates of a full commercial volume system. Due to its mechanical nature and modularity, we anticipate that one plant would have multiple modular CTS systems.

 

After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the technology or forming joint ventures with foreign domestic partners to build plants.

 

The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as the feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic suppliers, we anticipate that our profitability will be more consistent.

 

Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.

 

The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (EPA), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.02 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.

 

Section 45Z of the Inflation Reduction Act passed on August 16, 2022, offers a Clean Fuel Production Credit (CFPC) per gallon of transportation fuel produced with a base amount of 20 cents per gallon or $1 per gallon for a qualified facility that was built while paying at least prevailing wages and which met apprenticeship requirements. For sustainable aviation fuel, those figures are 35 cents and $1.75 per gallon respectively. The Company plans to apply for CFPC credits when it begins building its commercial facilities. The CFPC currently does not apply to transportation fuel sold after December 31, 2027. 

 

A Low Carbon Fuel Standard Credit (LCFS) is offered by various states (primarily California) for any amount of reduced CO2 in the production lifecycle of transportation fuels as compared to the amount of CO2 emitted in the production lifecycle of fossil fuels. The production lifecycle includes transportation costs to the point of use. California is currently offering around $72.50 per metric ton of CO2 reduction. When it is closer to commercial production, the Company plans to analyze the cost effectiveness of applying for these LCFS credits to determine in which state it could earn the most credits.

 

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has not generated any material revenues from its business.

 

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
GOING CONCERN
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 2 – GOING CONCERN

 

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of June 30, 2023, the Company has incurred accumulated losses of $54,999,875. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. These factors, among others, raise substantial doubt as to the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.

 

Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities, and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, or sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our supply chain, employees, and potential future customers. Our office and lab have remained open during the pandemic. Nevertheless, the pandemic slowed our ability to commercialize our process in two ways: by adversely affecting our ability to raise capital, and by adversely affecting the supply chain of laboratory equipment and various parts of upgrades to our CTS system, which slowed the development of our prototypes. Supply chain issues also delayed the delivery of various parts of our pilot plant. The extent to which our operations may be further impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the effects of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

 

 

Cash and Cash Equivalents

 

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

 

Stock Compensation

 

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

 

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

 

The stock compensation issued for services during the quarter ended June 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the quarter ended June 30, 2023:

 

   2/10/23   2/14/23   3/1/23   3/31/23   4/5/23   4/11/23 
Risk-free interest rate   3.93%   3.77%   4.01%   3.60%   3.30%   3.54%
Expected life   5 years    10 years    10 years    5 years    10 years    5 years 
Expected dividends   0%   0%   0%   0%   0%   0%
Expected volatility   123.25%   123.26%   123.52%   120.71%   119.51%   119.39%
BIOF common stock fair value  $0.159   $0.159   $0.177   $0.166   $0.154   $0.145 

 

   4/26/23   6/5/23   7/13/23 
Risk-free interest rate   3.46%   3.82%   3.82%
Expected life   5 years    7 years    5 years 
Expected dividends   0%   0%   0%
Expected volatility   119.28%   103.20%   90.70%
BIOF common stock fair value  $0.165   $0.170   $0.160 

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 

Patent Capitalization

 

If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $234,730 as of June 30, 2023 and $222,109 as of December 31, 2022.

 

Research and Development

 

The Company expenses all research and development costs as incurred. For the six months ended June 30, 2023, and June 30, 2022, the amounts charged to research and development expenses were $1,447,276 and $1,666,632, respectively.

 

Revenue Recognition

 

The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:

 

  1. persuasive evidence of an arrangement exists;
  2. the product has been shipped or the services have been rendered to the customer;
  3. the sales price is fixed or determinable; and,
  4. collectability is reasonably assured.

 

 

Common Stock Purchase Warrants and Other Derivative Financial Instruments

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Profit (Loss) per Common Share:

 

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

 

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
PROPERTY AND EQUIPMENT
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

NOTE 4 – PROPERTY AND EQUIPMENT

 

PROPERTY AND EQUIPMENT  Life  June 30, 2023   December 31, 2022 
Building and Improvements  15  $9,370   $9,370 
Machinery and Equipment  10  $791,540   $512,450 
Furniture and Fixtures  5  $13,649   $13,649 
Computer Equipment  3  $11,824   $11,824 
Property and Equipment, gross     $826,383   $547,293 
Less Accumulated Depreciation     $(184,283)  $(127,178)
Property and Equipment     $642,100   $420,115 

 

Total depreciation expense was $59,684 for the six months ended June 30, 2023.

 

In the six months ended June 30, 2023, The Company purchased machinery worth $285,538. This was primarily related to the pilot plant. The Company disposed of machinery that was no longer in use for a total of $3,500 that originally was purchased for $6,448 and that had accumulated depreciation of $2,579, thereby taking a loss of $369 on the disposal of assets.

 

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
PATENTS
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
PATENTS

NOTE 5 – PATENTS

 

The Company has been granted one patent on its technology and one continuation patent, has filed for three others that are pending, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $234,730 as of June 30, 2023.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
DEBT
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
DEBT

NOTE 6 – DEBT

 

Notes Payable – Related Parties

 

In July 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $25,000, that is to be repaid when the Company receives an equity investment of at least $3 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 every 12 months instead of interest, with a minimum of 50,000 warrants. It may convert into common stock at $0.13/share at the option of the holder for a total of 192,308 shares.

 

In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $50,000, that is to be repaid when the Company receives $5 million in equity investment. The Note carries a 10% interest per annum. The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants.

 

In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $100,000, that if it’s not paid by December 6, 2023, it automatically extends for another 6 months. It’s convertible at the option of the lender into common stock at $0.13/share for a total of 769,231 shares.

 

In April 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $150,000, that is to be repaid when the Company receives an equity investment of at least $1.5 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 100,000 every 6 months instead of interest. It may convert into common stock at $0.13/share at the option of the holder for a total of 1,153,846 shares.

 

In January 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $250,000, that if it’s not paid by July 4, 2023, it converts at the option of the Company into common stock at $0.13/share for a total of 1,923,077 shares.

 

In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the notes was $278,794.68. The notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, & Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company.

 

On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of future gross revenues to satisfy this note in full.

 

 

On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

Notes Payable – Other

 

In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the note was $14,382.2. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.

 

In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carried an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $39,500. In May 2018, the company made two principal payments totaling $40,000. The note went into default on June 1, 2018, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company.

 

In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to settle both notes.

 

 

On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $32,000 to $20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019.

 

A summary of all debts indicated in the Notes above is as follows:

 

Notes Payable 

June 30, 2023

  

December 31, 2022

 
Short Term Convertible Note – Related Party  $350,000   $0 
Short Term Chapter 11 Settlement  $0   $50,000 
Long Term Notes Payable after capital investment received  $200,000   $0 
Long Term Notes Payable from future revenue — Related Party  $1,700,630   $1,700,630 
Long Term Notes Payable from future revenue — Other  $120,000   $120,000 
Long Term Note Payable from future profits — Related Party  $820,932   $820,932 
Long Term Note Payable from future profits — Other  $96,570   $96,570 
TOTAL NOTES  $3,288,132   $2,788,132 

 

Of the $3,288,132 payable as of June 30, 2023, $2,738,132 is due out of future revenue or future profits with no specific due date, and another $200,000 is due only after a significant capital investment. $2,417,502 of the $2,788,132 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would not be discharged is $670,630, consisting of $550,630 due to related parties, and $120,000 due to others.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
STOCKHOLDERS’ EQUITY
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 7 – STOCKHOLDERS’ EQUITY

 

The total number of shares of capital stock, which the Company has authority to issue, is 1,010 million, 1 billion of which are designated as common stock at $0.001 par value (the “Common Stock”) and 10 million of which are designated as preferred stock par value $0.001 (the “Preferred Stock”). As of June 30, 2023, the Company had 300,584,297 shares of Common Stock issued and outstanding and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.

 

For the six months ended June 30, 2023, the Company issued an aggregate of 174,191 shares of its common stock for services valued at $29,300.

 

For the six months ended June 30, 2023, 314,000 warrants were issued for services. Using a Black-Scholes asset pricing model, these had a value of $42,634.

 

For the six months ended June 30, 2023, 4,518,332 shares of common stock were issued for cash of $677,771.

 

For the six months ended June 30, 2023, 5,950,148 warrants were exercised for proceeds of $97,250.

 

For the six months ended June 30, 2023, 2,067,999 warrants expired.

 

For the six months ended June 30, 2023, 7,050,000 unvested options expired.

 

For the six months ended June 30, 2023, 4,385,000 stock options vested. Using a Black-Scholes asset pricing model, these had a value of $637,028.

 

For the six months ended June 30, 2023, 15,950,000 stock options were issued and unvested. Using a Black-Scholes asset pricing model, these have a value of $2,675,116.

 

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 8 - COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. The Company is not in any litigation at this time.

 

Leases

 

The Company currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period was for twenty-four (24) months from November 1, 2019, to October 31, 2021. This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024. Annual rent commenced at $84,100 per annum and increased 3% per year. The latest amendment adjusted to lease to $102,950 per annum and increases at 3% per year. Tenant is also required to cover operating costs that are estimated at $3,600 per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General & Administrative expenses.

 

ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

 

In addition, the Company leases land in Arcadia, FL where it grows king grass. The original lease began on September 1, 2020, and was for 18.2 acres at an annual cost of $6,370 that the Company has the right to renew for a total of 5 years. A second lease began on March 31, 2023, for an additional 167.6 acres at a cost of $24,721 every 6 months that the Company also can continue for up to 5 years. Since those leases can be terminated at will, they are not included in the ROU or lease liability on the Company’s balance sheet.

 

Rent expense for the six months ending June 30, 2023, and 2022, were $108,893 and $64,724, respectively.

 

The Company recognized the following related to leases in its Consolidated Balance Sheet:

 

PERIOD ENDED 

June 30, 2023

  

December 31, 2022

 
Right of Use Lease Liabilities          
Current portion   99,626    95,172 
Long-term portion   34,909    85,983 
TOTAL   134,535    181,155 

 

As of June 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:

 

YEAR ENDED 

MINIMUM

DUE

 
2023   48,552 
2024   85,983 
2025   0 
      
TOTAL  $134,535 

 

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

 

Related Party Transactions

 

The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

  1) Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 6.
  2) A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they continued to receive less than full salaries.

 

The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:

 

From July 1, 2023, to the date of this filing, the Company received an SBIR Phase I grant from the Department of Energy valued at $206,500.

 

From July 1, 2023, to the date of this filing, the Company issued 0 shares for services.

 

From July 1, 2023, to the date of this filing, 125,000 options expired.

 

From July 1, 2023, to the date of this filing, 1,200,000 unvested options were issued at an exercise price of 16 cents per share and expiration dates of 5 and 10 years. Using the Black-Scholes option pricing model, they were valued at $160,497.

 

From July 1, 2023, to the date of this filing, the Company issued 500,000 shares in a private placement for proceeds of $75,000.

 

From July 1, 2023, to the date of this filing, the Company issued convertible notes to related parties for $25,000. Instead of interest, it accrues warrants at the rate of 50,000 per year. Those warrants were valued at $5,812 using the Black Scholes option pricing model.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.

 

Principles of Consolidation

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

 

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

 

Stock Compensation

Stock Compensation

 

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

 

Stock-based Compensation Valuation Methodology

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

 

The stock compensation issued for services during the quarter ended June 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the quarter ended June 30, 2023:

 

   2/10/23   2/14/23   3/1/23   3/31/23   4/5/23   4/11/23 
Risk-free interest rate   3.93%   3.77%   4.01%   3.60%   3.30%   3.54%
Expected life   5 years    10 years    10 years    5 years    10 years    5 years 
Expected dividends   0%   0%   0%   0%   0%   0%
Expected volatility   123.25%   123.26%   123.52%   120.71%   119.51%   119.39%
BIOF common stock fair value  $0.159   $0.159   $0.177   $0.166   $0.154   $0.145 

 

   4/26/23   6/5/23   7/13/23 
Risk-free interest rate   3.46%   3.82%   3.82%
Expected life   5 years    7 years    5 years 
Expected dividends   0%   0%   0%
Expected volatility   119.28%   103.20%   90.70%
BIOF common stock fair value  $0.165   $0.170   $0.160 

 

Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 

Patent Capitalization

Patent Capitalization

 

If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $234,730 as of June 30, 2023 and $222,109 as of December 31, 2022.

 

Research and Development

Research and Development

 

The Company expenses all research and development costs as incurred. For the six months ended June 30, 2023, and June 30, 2022, the amounts charged to research and development expenses were $1,447,276 and $1,666,632, respectively.

 

Revenue Recognition

Revenue Recognition

 

The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:

 

  1. persuasive evidence of an arrangement exists;
  2. the product has been shipped or the services have been rendered to the customer;
  3. the sales price is fixed or determinable; and,
  4. collectability is reasonably assured.

 

 

Common Stock Purchase Warrants and Other Derivative Financial Instruments

Common Stock Purchase Warrants and Other Derivative Financial Instruments

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

 

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

 

Income Taxes

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Profit (Loss) per Common Share:

Profit (Loss) per Common Share:

 

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

 

Fair Value Measurements

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION

The stock compensation issued for services during the quarter ended June 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the quarter ended June 30, 2023:

 

   2/10/23   2/14/23   3/1/23   3/31/23   4/5/23   4/11/23 
Risk-free interest rate   3.93%   3.77%   4.01%   3.60%   3.30%   3.54%
Expected life   5 years    10 years    10 years    5 years    10 years    5 years 
Expected dividends   0%   0%   0%   0%   0%   0%
Expected volatility   123.25%   123.26%   123.52%   120.71%   119.51%   119.39%
BIOF common stock fair value  $0.159   $0.159   $0.177   $0.166   $0.154   $0.145 

 

   4/26/23   6/5/23   7/13/23 
Risk-free interest rate   3.46%   3.82%   3.82%
Expected life   5 years    7 years    5 years 
Expected dividends   0%   0%   0%
Expected volatility   119.28%   103.20%   90.70%
BIOF common stock fair value  $0.165   $0.170   $0.160 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
PROPERTY AND EQUIPMENT (Tables)
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

 

PROPERTY AND EQUIPMENT  Life  June 30, 2023   December 31, 2022 
Building and Improvements  15  $9,370   $9,370 
Machinery and Equipment  10  $791,540   $512,450 
Furniture and Fixtures  5  $13,649   $13,649 
Computer Equipment  3  $11,824   $11,824 
Property and Equipment, gross     $826,383   $547,293 
Less Accumulated Depreciation     $(184,283)  $(127,178)
Property and Equipment     $642,100   $420,115 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
DEBT (Tables)
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
SCHEDULE OF NOTES PAYABLE

A summary of all debts indicated in the Notes above is as follows:

 

Notes Payable 

June 30, 2023

  

December 31, 2022

 
Short Term Convertible Note – Related Party  $350,000   $0 
Short Term Chapter 11 Settlement  $0   $50,000 
Long Term Notes Payable after capital investment received  $200,000   $0 
Long Term Notes Payable from future revenue — Related Party  $1,700,630   $1,700,630 
Long Term Notes Payable from future revenue — Other  $120,000   $120,000 
Long Term Note Payable from future profits — Related Party  $820,932   $820,932 
Long Term Note Payable from future profits — Other  $96,570   $96,570 
TOTAL NOTES  $3,288,132   $2,788,132 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES (Tables)
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET

The Company recognized the following related to leases in its Consolidated Balance Sheet:

 

PERIOD ENDED 

June 30, 2023

  

December 31, 2022

 
Right of Use Lease Liabilities          
Current portion   99,626    95,172 
Long-term portion   34,909    85,983 
TOTAL   134,535    181,155 
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS

As of June 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:

 

YEAR ENDED 

MINIMUM

DUE

 
2023   48,552 
2024   85,983 
2025   0 
      
TOTAL  $134,535 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION (Details Narrative)
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Renewable fuel description This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.02 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
GOING CONCERN (Details Narrative) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated losses $ 54,999,875 $ 52,781,586
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) - Warrant [Member]
6 Months Ended
Jun. 30, 2023
$ / shares
Issuance Date 2/10/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.93%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 123.25%
BIOF common stock fair value $ 0.159
Issuance Date 2/14/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.77%
Expected life 10 years
Expected dividends 0.00%
Expected volatility 123.26%
BIOF common stock fair value $ 0.159
Issuance Date 3/1/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 4.01%
Expected life 10 years
Expected dividends 0.00%
Expected volatility 123.52%
BIOF common stock fair value $ 0.177
Issuance Date 3/31/2023 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.60%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 120.71%
BIOF common stock fair value $ 0.166
Issuance Date 4/5/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.30%
Expected life 10 years
Expected dividends 0.00%
Expected volatility 119.51%
BIOF common stock fair value $ 0.154
Issuance Date 4/11/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.54%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 119.39%
BIOF common stock fair value $ 0.145
Issuance Date 4/26/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.46%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 119.28%
BIOF common stock fair value $ 0.165
Issuance Date 6/5/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.82%
Expected life 7 years
Expected dividends 0.00%
Expected volatility 103.20%
BIOF common stock fair value $ 0.170
Issuance Date 7/13/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.82%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 90.70%
BIOF common stock fair value $ 0.160
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]          
Patents $ 234,730   $ 234,730   $ 222,109
Research and development expenses $ 762,714 $ 436,480 $ 1,447,276 $ 1,666,632  
Minimum [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment, estimated useful life 5 years   5 years    
Maximum [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment, estimated useful life 10 years   10 years    
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 826,383 $ 547,293
Less Accumulated Depreciation (184,283) (127,178)
Property and Equipment 642,100 420,115
Building Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 9,370 9,370
Estimated Useful Lives 15 years  
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 791,540 512,450
Estimated Useful Lives 10 years  
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 13,649 13,649
Estimated Useful Lives 5 years  
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 11,824 $ 11,824
Estimated Useful Lives 3 years  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Depreciation $ 59,684  
Purchase value 826,383 $ 547,293
Pilot Plant [Member]    
Property, Plant and Equipment [Line Items]    
Purchase of machinery 285,538  
Machinery [Member]    
Property, Plant and Equipment [Line Items]    
Disposal of machinery 3,500  
Purchase value 6,448  
Accumulated depreciation 2,579  
Loss on disposal of assets $ 369  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
PATENTS (Details Narrative) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Finite-Lived Patents, Gross $ 234,730 $ 222,109
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
SCHEDULE OF NOTES PAYABLE (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
Short Term Convertible Note – Related Party $ 350,000 $ 0
Short Term Chapter 11 Settlement 0 50,000
Long Term Notes Payable after capital investment received 200,000 0
Long Term Notes Payable from future revenue — Related Party 1,700,630 1,700,630
Long Term Notes Payable from future revenue — Other 120,000 120,000
Long Term Note Payable from future profits — Related Party 820,932 820,932
Long Term Note Payable from future profits — Other 96,570 96,570
TOTAL NOTES $ 3,288,132 $ 2,788,132
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Dec. 31, 2022
Equity [Abstract]            
Capital units, authorized 1,010,000,000       1,010,000,000  
Common stock, shares authorized 1,000,000,000       1,000,000,000 1,000,000,000
Common stock, par value $ 0.001       $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000       10,000,000 10,000,000
Preferred stock, par value $ 0.001       $ 0.001 $ 0.001
Common stock, shares issued 300,584,297       300,584,297 289,941,623
Common stock, shares outstanding 300,584,297       300,584,297 289,941,623
Preferred stock, shares Issued 0       0 0
Number of shares issued for services, shares         174,191  
Number of shares issued for services, value $ 5,300 $ 24,000 $ 16,150 $ 71,300 $ 29,300  
Warrants issued for services 314,000       314,000  
Warrants issued for services, value         $ 42,634  
Issuance of common stock and warrants for cash through PPM, shares         4,518,332  
Issuance of common stock and warrants for cash through PPM $ 95,022 582,750 $ 675,000   $ 677,771  
Warrants exercised share, shares         5,950,148  
Warrants exercised $ 25,000 $ 72,250     $ 97,250  
Number of warrants expired         2,067,999  
Unvested options expired         7,050,000  
Number of stock options vested, shares 2,000,000 2,385,000 800,000 10,560,000 4,385,000  
Number of stock options vested, value         $ 637,028  
Number of shares unvested 15,950,000       15,950,000  
Options issued and unvested value         $ 2,675,116  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Current portion $ 99,626 $ 95,172
Long-term portion 34,909 85,983
TOTAL $ 134,535 $ 181,155
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)
Jun. 30, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2023 $ 48,552
2024 85,983
2025 0
TOTAL $ 134,535
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES (Details Narrative)
6 Months Ended
Sep. 01, 2020
USD ($)
a
Jun. 30, 2023
USD ($)
a
Jun. 30, 2022
USD ($)
Property, Plant and Equipment [Line Items]      
Annual rent   $ 84,100  
Percentage of increase in rent per year   3.00%  
Operating costs   $ 3,600  
Acres | a 18.2 167.6  
Lease cost $ 6,370 $ 24,721  
Lease renewal term 5 years 5 years  
Rent expense   $ 108,893 $ 64,724
Office and Laboratory Space [Member]      
Property, Plant and Equipment [Line Items]      
Lease extension period   This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024.  
Percentage of increase in rent per year   3.00%  
Lease expense   $ 102,950  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
6 Months Ended
Jul. 01, 2023
Jun. 30, 2023
Subsequent Event [Line Items]    
Shares issued for services   174,191
Subsequent Event [Member]    
Subsequent Event [Line Items]    
Shares issued for services 0  
Stock options expired 125,000  
Number of unvested shares issued 1,200,000  
Exercise price $ 16  
Number of unvested shares issued, value $ 160,497  
Number of shares issued for private placement 500,000  
Proceeds from issuance of private placement $ 75,000  
Subsequent Event [Member] | Related Party [Member]    
Subsequent Event [Line Items]    
Convertible note $ 25,000  
Conversion of convertible note into shares 50,000  
Warrants valued 5,812  
Subsequent Event [Member] | Minimum [Member]    
Subsequent Event [Line Items]    
Expiration date 5 years  
Subsequent Event [Member] | Maximum [Member]    
Subsequent Event [Line Items]    
Expiration date 10 years  
Subsequent Event [Member] | SBIR Phase I Grant [Member]    
Subsequent Event [Line Items]    
SBIR phase I grants $ 206,500  
XML 46 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001549145 2023-01-01 2023-06-30 0001549145 2023-08-05 0001549145 2023-06-30 0001549145 2022-12-31 0001549145 us-gaap:NonrelatedPartyMember 2023-06-30 0001549145 us-gaap:NonrelatedPartyMember 2022-12-31 0001549145 us-gaap:RelatedPartyMember 2023-06-30 0001549145 us-gaap:RelatedPartyMember 2022-12-31 0001549145 2023-04-01 2023-06-30 0001549145 2022-04-01 2022-06-30 0001549145 2022-01-01 2022-06-30 0001549145 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001549145 us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001549145 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001549145 us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001549145 us-gaap:CommonStockMember 2022-12-31 0001549145 us-gaap:PreferredStockMember 2022-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001549145 us-gaap:RetainedEarningsMember 2022-12-31 0001549145 us-gaap:CommonStockMember 2023-03-31 0001549145 us-gaap:PreferredStockMember 2023-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001549145 us-gaap:RetainedEarningsMember 2023-03-31 0001549145 2023-03-31 0001549145 us-gaap:CommonStockMember 2021-12-31 0001549145 us-gaap:PreferredStockMember 2021-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001549145 us-gaap:RetainedEarningsMember 2021-12-31 0001549145 2021-12-31 0001549145 us-gaap:CommonStockMember 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-03-31 0001549145 2022-03-31 0001549145 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001549145 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001549145 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001549145 2023-01-01 2023-03-31 0001549145 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001549145 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001549145 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001549145 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001549145 2022-01-01 2022-03-31 0001549145 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001549145 us-gaap:CommonStockMember 2023-06-30 0001549145 us-gaap:PreferredStockMember 2023-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001549145 us-gaap:RetainedEarningsMember 2023-06-30 0001549145 us-gaap:CommonStockMember 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-06-30 0001549145 2022-06-30 0001549145 BIOF:IssuanceDateFebruaryTenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateMarchOneTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateAprilFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateAprilElevenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateFebruaryTenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateMarchOneTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateAprilFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateAprilElevenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateJuneFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateJulyThirteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001549145 BIOF:IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateJuneFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 BIOF:IssuanceDateJulyThirteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-06-30 0001549145 srt:MinimumMember 2023-06-30 0001549145 srt:MaximumMember 2023-06-30 0001549145 us-gaap:BuildingImprovementsMember 2023-06-30 0001549145 us-gaap:BuildingImprovementsMember 2022-12-31 0001549145 us-gaap:MachineryAndEquipmentMember 2023-06-30 0001549145 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001549145 us-gaap:FurnitureAndFixturesMember 2023-06-30 0001549145 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001549145 us-gaap:ComputerEquipmentMember 2023-06-30 0001549145 us-gaap:ComputerEquipmentMember 2022-12-31 0001549145 BIOF:PilotPlantMember 2023-01-01 2023-06-30 0001549145 BIOF:MachineryMember 2023-01-01 2023-06-30 0001549145 BIOF:MachineryMember 2023-06-30 0001549145 BIOF:OfficeAndLaboratorySpaceMember 2023-01-01 2023-06-30 0001549145 2020-09-01 0001549145 2020-09-01 2020-09-01 0001549145 BIOF:SBIRPhaseIGrantMember us-gaap:SubsequentEventMember 2023-07-01 2023-07-01 0001549145 us-gaap:SubsequentEventMember 2023-07-01 2023-07-01 0001549145 srt:MinimumMember us-gaap:SubsequentEventMember 2023-07-01 2023-07-01 0001549145 srt:MaximumMember us-gaap:SubsequentEventMember 2023-07-01 2023-07-01 0001549145 us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2023-07-01 0001549145 us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2023-07-01 2023-07-01 iso4217:USD shares iso4217:USD shares pure utr:acre 0001549145 false --12-31 Q2 true false 10-Q 2023-06-30 2023 000-54942 BLUE BIOFUELS, INC. NV 45-4944960 3710 Buckeye Street Suite 120 Palm Beach Gardens FL 33410 (888) 607-3555 Common Stock par value $0.001 BIOF Yes Yes Non-accelerated Filer false true false 301084297 61677 211901 61118 43119 122795 255020 184283 127178 642100 420115 30276 30276 129745 178399 234730 222109 1036851 850899 1159646 1105919 14735 37135 72670 72670 72670 72670 638076 307606 99626 95172 50000 350000 102718 76138 1277825 638721 34909 85983 2721562 2521562 216570 216570 2973041 2824115 4250866 3462836 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 1000000000 1000000000 300584297 300584297 289941623 289941623 300584 289942 51608070 50134727 -54999875 -52781586 -3091221 -2356917 -3091221 -2356917 1159646 1105919 355324 241507 725169 1044571 762714 436480 1447276 1666632 -40099 -369 -40099 1118038 718086 2172813 2751302 -1118038 -718086 -2172813 -2751302 33783 6712 40495 13424 2378 592 4981 1621 -36161 -7304 -45475 -15045 -1154199 -725390 -2218288 -2766347 -1154199 -725390 -2218288 -2766347 -0.004 -0.003 -0.007 -0.010 -0.003 -0.002 -0.006 -0.008 297635565 275876745 297635565 275876745 351822695 331481205 351822695 331481205 289941623 289942 50134727 -52781586 -2356917 140000 140 23860 24000 3884998 3885 578865 582750 5450148 5450 66800 72250 2385000 391297 391297 -1064090 -1064090 299416769 299417 51195549 -53845676 -2350710 34194 34 5266 5300 2000000 245732 245732 633334 633 94389 95022 314000 42634 42634 500000 500 24500 25000 -1154199 -1154199 300584297 300584 51608069 -54999875 -3091221 274003883 274004 47151353 -48821403 -1396046 447781 448 70852 71300 150000 150 7350 7500 10560000 1316277 1316277 -2040957 -2040957 274601664 274602 48545832 -50862360 -2041926 274601664 274602 48545832 -50862360 -2041926 78600 79 16071 16150 200000 200 8200 8400 800000 99106 99106 99106 99106 4499999 4500 670500 675000 -725390 -725390 279380263 279380 49339710 -51587750 -1968660 279380263 279380 49339710 -51587750 -1968660 -2218288 -2766347 59684 68123 29300 87450 679662 1415383 50000 -369 -40099 18000 66896 26581 13424 308070 45753 2035 -42974 -1180587 -1205985 282038 2400 12621 18273 -294659 -20673 97250 15900 550000 677772 675000 1325022 690900 -150224 -535758 211901 1164664 61677 628906 <p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zRr0ncLy1QE2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_827_zLjUHe93fKq5">ORGANIZATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In early 2018, the Company’s chief executive officer (“CEO”) Ben Slager invented a new technology system referred to as Cellulose-to-Sugar or CTS, and the Company filed a process patent application for this technology. Mr. Slager has since further developed the system with laboratory personnel. The CTS patent was awarded in 2021 in the United States (U.S. Patent No. 10,994,255) and also in El Salvador. The Company also filed this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, Japan, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. In addition to this patent, the Company has received one additional patent (for which it has also applied for in all the above-mentioned jurisdictions). Further, the company has filed for 4 other patents which are currently pending.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for breaking down cellulosic material for conversion into biofuels. CTS can break down any cellulosic material – including grasses and agricultural waste. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CTS is environmentally friendly in that it recycles the water and catalyst, and it has a low carbon footprint: the amount of added atmospheric carbon created by burning the biofuels produced by the CTS system was absorbed by the plant-based feedstock while growing and is merely released back into the atmosphere. No extra CO2 is released into the atmosphere when our biofuels are burned. This is to be distinguished from fossil fuels because new CO2 is released when fossil fuels are burned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At a commercial scale, our management expects to be able to produce ethanol at a lower cost per gallon than existing commercial corn or cellulosic ethanol producers due to the fact that the CTS process is robust, uncomplicated and efficient, and is expected to use low-cost feedstocks and have a potentially high value by-product, lignin. We believe a significant difference between CTS ethanol and corn ethanol is the wide range of abundantly available feedstocks that CTS can process compared to just corn as the feedstock. The CTS feedstocks are nonfood and have much lower costs than corn. In addition, while in corn ethanol only the corn kernels are used, CTS uses the whole plant or its waste products, meaning it could obtain much higher yields per acre. The Company also expects to potentially receive a highly valued D3 RIN for each gallon of ethanol it produces.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, the Company partnered with K.R. Komarek to build its CTS machines going forward. In 2023, the Company completed the build-out of a pilot plant based on a modified Komarek machine and is in the process of further testing and optimizing the plant. Komarek is an industry leading manufacturing company that builds briquetting machines and compaction/granulation systems with throughput capacities up to 50 tons per hour.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF). The license agreement with Vertimass is the subject to a confidentiality agreement between the parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Plan of Operation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will prioritize building an SAF facility to generate revenue sooner. First, the Company intends to build a commercial scale ethanol to SAF facility and subsequently build commercial CTS and ethanol facilities on the front-end of that to produce cellulosic SAF and generate the large D7 RIN and other government credits.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing commercial production will require project financing. The project financing is planned to initially be for setting up a 10 million gallon per year production facility for converting ethanol into jet fuel using the Vertimass Process that the Company has licensed. Parallel to that, the Company plans to build a semicommercial CTS demonstration plant that integrates a larger CTS system into the pre-processing and post-processing elements of the plant. The goal of the semi-commercial plant is to finalize design and operational parameters at this volume level and to provide operating cost estimates of a full commercial volume system. Due to its mechanical nature and modularity, we anticipate that one plant would have multiple modular CTS systems.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the technology or forming joint ventures with foreign domestic partners to build plants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as the feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic suppliers, we anticipate that our profitability will be more consistent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (EPA), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. <span id="xdx_903_ecustom--RenewableFuelDescription_c20230101__20230630_zTNaFWOHpnRg" title="Renewable fuel description">This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.02 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 45Z of the Inflation Reduction Act passed on August 16, 2022, offers a Clean Fuel Production Credit (CFPC) per gallon of transportation fuel produced with a base amount of 20 cents per gallon or $1 per gallon for a qualified facility that was built while paying at least prevailing wages and which met apprenticeship requirements. For sustainable aviation fuel, those figures are 35 cents and $1.75 per gallon respectively. The Company plans to apply for CFPC credits when it begins building its commercial facilities. The CFPC currently does not apply to transportation fuel sold after December 31, 2027. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Low Carbon Fuel Standard Credit (LCFS) is offered by various states (primarily California) for any amount of reduced CO2 in the production lifecycle of transportation fuels as compared to the amount of CO2 emitted in the production lifecycle of fossil fuels. The production lifecycle includes transportation costs to the point of use. California is currently offering around $72.50 per metric ton of CO2 reduction. When it is closer to commercial production, the Company plans to analyze the cost effectiveness of applying for these LCFS credits to determine in which state it could earn the most credits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has not generated any material revenues from its business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.02 per gallon of ethanol. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation <p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zJ3zJNaiNZy" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_82B_z1LhUaYMCHzc">GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of June 30, 2023, the Company has incurred accumulated losses of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230630_zNCzJxS7gvC8" title="Accumulated losses">54,999,875</span>. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. These factors, among others, raise substantial doubt as to the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities, and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, or sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our supply chain, employees, and potential future customers. Our office and lab have remained open during the pandemic. Nevertheless, the pandemic slowed our ability to commercialize our process in two ways: by adversely affecting our ability to raise capital, and by adversely affecting the supply chain of laboratory equipment and various parts of upgrades to our CTS system, which slowed the development of our prototypes. Supply chain issues also delayed the delivery of various parts of our pilot plant. The extent to which our operations may be further impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the effects of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -54999875 <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zaS1s1uKtMJ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_823_zGvbervGQ1v2">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zPYjg96wp8Nh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zxbOJ6HjAKw2">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_z4I0gwIG9Gx2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z4r4moHLrbO6">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--UseOfEstimates_zcNIP7auowQ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zL8TDNUXVt7e">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zWuOL5XeCQOj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zdOfGZCRgeni">Cash and Cash Equivalents</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zCyEmA62iJAg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zrvn3TBOiTB4">Stock Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--StockbasedCompensationValuationMethodologyPolicyTextBlock_zPFDdqTZz9Q8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zyAuDPLBXVC9">Stock-based Compensation Valuation Methodology</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zudY6yZB6sAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock compensation issued for services during the quarter ended June 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the quarter ended June 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z1h0H1lhPHqi" style="display: none">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2/10/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2/14/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3/1/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3/31/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/5/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/11/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSh7S7Tms59" style="width: 7%; text-align: right" title="Risk-free interest rate">3.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmu6jPmbvss7" style="width: 7%; text-align: right" title="Risk-free interest rate">3.77</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzSJrKFkwgJ6" style="width: 7%; text-align: right" title="Risk-free interest rate">4.01</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTP0tYgqhT88" style="width: 7%; text-align: right" title="Risk-free interest rate">3.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt62Qvq9l85k" style="width: 7%; text-align: right" title="Risk-free interest rate">3.30</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFeTV9EYERPj" style="width: 7%; text-align: right" title="Risk-free interest rate">3.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw9VQULeBri" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXetxd1gWHv4" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxsyVy3t8Zb9" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQhfmS8KQ8T2" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztR3YyKh7qOa" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYXOMldwIJw" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPgI1dbIDhv4" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3qAMeHl73X3" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXbu1iw1jzLj" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAeTUn3xwZC1" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zepMUN2EpYJl" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaOXBYdwNd6c" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEWkWH0PCXYj" style="text-align: right" title="Expected volatility">123.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcxOYmnPuje8" style="text-align: right" title="Expected volatility">123.26</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1PybiXuIqBh" style="text-align: right" title="Expected volatility">123.52</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmcOd2SRLADj" style="text-align: right" title="Expected volatility">120.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwysi6ZLJ4bd" style="text-align: right" title="Expected volatility">119.51</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUKLTZyMCxy1" style="text-align: right" title="Expected volatility">119.39</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkwZ4eAm88je" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4HWYfJ9dSy3" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWh0rCAumKCg" style="text-align: right" title="BIOF common stock fair value">0.177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUHXbo6wHkY" style="text-align: right" title="BIOF common stock fair value">0.166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zleVRmi0cgZj" style="text-align: right" title="BIOF common stock fair value">0.154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlKCSMvDfoKe" style="text-align: right" title="BIOF common stock fair value">0.145</td><td style="text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 67%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/26/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6/5/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">7/13/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMW51iEO8fQi" style="width: 13%; text-align: right" title="Risk-free interest rate">3.46</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTBrL3Ug0Bx1" style="width: 13%; text-align: right" title="Risk-free interest rate">3.82</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEXYKsKLdEvf" style="width: 13%; text-align: right" title="Risk-free interest rate">3.82</td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zULfI4iAs1q4" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziiOGCIqg3De" title="Expected life">7</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8mhFRZz9d73" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zboc8JHbfnI6" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9hBLiusTTse" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlugNh12LpE" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGxsU93CmPbk" style="text-align: right" title="Expected volatility">119.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfBlVxYpC4rh" style="text-align: right" title="Expected volatility">103.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z91Pt3Op3qFk" style="text-align: right" title="Expected volatility">90.70</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx5Td0OyoRfa" style="text-align: right" title="BIOF common stock fair value">0.165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0oxL80N7uI8" style="text-align: right" title="BIOF common stock fair value">0.170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUqdE7DJX6Ql" style="text-align: right" title="BIOF common stock fair value">0.160</td><td style="text-align: left"> </td> </tr> </table> <p id="xdx_8A4_zA6GlPYKHmtf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zVXFUBhNzYth" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zvihgy4MnHt3">Property and Equipment</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__srt--RangeAxis__srt--MinimumMember_zyZj06cKlegh" title="Property and equipment, estimated useful life">5</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__srt--RangeAxis__srt--MaximumMember_z8kHG9lYifJ9" title="Property and equipment, estimated useful life">10</span> years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zOsfLvrlkGpd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zaZIVqxhF6x4">Patent Capitalization</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $<span id="xdx_90C_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20230630_zD4TCFVM1FCa" title="Patents">234,730</span> as of June 30, 2023 and $<span id="xdx_90B_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20221231_ztKrICflswB" title="Patents">222,109</span> as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zjf2XNGQ7Ra5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zlCStzD5zQ64">Research and Development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses all research and development costs as incurred. For the six months ended June 30, 2023, and June 30, 2022, the amounts charged to research and development expenses were $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230630_zwm0hloMHhkf" title="Research and development expenses">1,447,276 </span>and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20220630_zHa71dEOgrFa" title="Research and development expenses">1,666,632</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zO1BJDE7OuLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zJLjEZUjywji">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persuasive evidence of an arrangement exists;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the product has been shipped or the services have been rendered to the customer;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sales price is fixed or determinable; and,</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collectability is reasonably assured.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_847_ecustom--CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock_zhuCryYJs4vh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_z56DeJZHppse">Common Stock Purchase Warrants and Other Derivative Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zaBxG1enJkK8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zPOoK5VDSxta">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z5CEXsQpk5wl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zUBHznJKrUzj">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zIYVBRzLjmV2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zUvIRwTQcoOg">Profit (Loss) per Common Share:</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcntm7SJtMua" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zOFwEw7q7jGh">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — quoted prices in active markets for identical assets or liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zbWUL9InKw0h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zBWRHW1BdzUe">Recent Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zPYjg96wp8Nh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zxbOJ6HjAKw2">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_z4I0gwIG9Gx2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z4r4moHLrbO6">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--UseOfEstimates_zcNIP7auowQ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zL8TDNUXVt7e">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zWuOL5XeCQOj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zdOfGZCRgeni">Cash and Cash Equivalents</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zCyEmA62iJAg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zrvn3TBOiTB4">Stock Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--StockbasedCompensationValuationMethodologyPolicyTextBlock_zPFDdqTZz9Q8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zyAuDPLBXVC9">Stock-based Compensation Valuation Methodology</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zudY6yZB6sAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock compensation issued for services during the quarter ended June 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the quarter ended June 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z1h0H1lhPHqi" style="display: none">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2/10/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2/14/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3/1/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3/31/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/5/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/11/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSh7S7Tms59" style="width: 7%; text-align: right" title="Risk-free interest rate">3.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmu6jPmbvss7" style="width: 7%; text-align: right" title="Risk-free interest rate">3.77</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzSJrKFkwgJ6" style="width: 7%; text-align: right" title="Risk-free interest rate">4.01</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTP0tYgqhT88" style="width: 7%; text-align: right" title="Risk-free interest rate">3.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt62Qvq9l85k" style="width: 7%; text-align: right" title="Risk-free interest rate">3.30</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFeTV9EYERPj" style="width: 7%; text-align: right" title="Risk-free interest rate">3.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw9VQULeBri" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXetxd1gWHv4" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxsyVy3t8Zb9" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQhfmS8KQ8T2" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztR3YyKh7qOa" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYXOMldwIJw" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPgI1dbIDhv4" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3qAMeHl73X3" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXbu1iw1jzLj" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAeTUn3xwZC1" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zepMUN2EpYJl" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaOXBYdwNd6c" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEWkWH0PCXYj" style="text-align: right" title="Expected volatility">123.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcxOYmnPuje8" style="text-align: right" title="Expected volatility">123.26</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1PybiXuIqBh" style="text-align: right" title="Expected volatility">123.52</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmcOd2SRLADj" style="text-align: right" title="Expected volatility">120.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwysi6ZLJ4bd" style="text-align: right" title="Expected volatility">119.51</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUKLTZyMCxy1" style="text-align: right" title="Expected volatility">119.39</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkwZ4eAm88je" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4HWYfJ9dSy3" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWh0rCAumKCg" style="text-align: right" title="BIOF common stock fair value">0.177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUHXbo6wHkY" style="text-align: right" title="BIOF common stock fair value">0.166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zleVRmi0cgZj" style="text-align: right" title="BIOF common stock fair value">0.154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlKCSMvDfoKe" style="text-align: right" title="BIOF common stock fair value">0.145</td><td style="text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 67%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/26/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6/5/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">7/13/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMW51iEO8fQi" style="width: 13%; text-align: right" title="Risk-free interest rate">3.46</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTBrL3Ug0Bx1" style="width: 13%; text-align: right" title="Risk-free interest rate">3.82</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEXYKsKLdEvf" style="width: 13%; text-align: right" title="Risk-free interest rate">3.82</td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zULfI4iAs1q4" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziiOGCIqg3De" title="Expected life">7</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8mhFRZz9d73" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zboc8JHbfnI6" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9hBLiusTTse" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlugNh12LpE" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGxsU93CmPbk" style="text-align: right" title="Expected volatility">119.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfBlVxYpC4rh" style="text-align: right" title="Expected volatility">103.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z91Pt3Op3qFk" style="text-align: right" title="Expected volatility">90.70</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx5Td0OyoRfa" style="text-align: right" title="BIOF common stock fair value">0.165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0oxL80N7uI8" style="text-align: right" title="BIOF common stock fair value">0.170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUqdE7DJX6Ql" style="text-align: right" title="BIOF common stock fair value">0.160</td><td style="text-align: left"> </td> </tr> </table> <p id="xdx_8A4_zA6GlPYKHmtf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zudY6yZB6sAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock compensation issued for services during the quarter ended June 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the quarter ended June 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z1h0H1lhPHqi" style="display: none">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2/10/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2/14/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3/1/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3/31/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/5/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/11/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSh7S7Tms59" style="width: 7%; text-align: right" title="Risk-free interest rate">3.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmu6jPmbvss7" style="width: 7%; text-align: right" title="Risk-free interest rate">3.77</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzSJrKFkwgJ6" style="width: 7%; text-align: right" title="Risk-free interest rate">4.01</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTP0tYgqhT88" style="width: 7%; text-align: right" title="Risk-free interest rate">3.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt62Qvq9l85k" style="width: 7%; text-align: right" title="Risk-free interest rate">3.30</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFeTV9EYERPj" style="width: 7%; text-align: right" title="Risk-free interest rate">3.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpw9VQULeBri" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXetxd1gWHv4" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxsyVy3t8Zb9" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQhfmS8KQ8T2" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztR3YyKh7qOa" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYXOMldwIJw" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPgI1dbIDhv4" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3qAMeHl73X3" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXbu1iw1jzLj" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAeTUn3xwZC1" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zepMUN2EpYJl" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaOXBYdwNd6c" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEWkWH0PCXYj" style="text-align: right" title="Expected volatility">123.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcxOYmnPuje8" style="text-align: right" title="Expected volatility">123.26</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1PybiXuIqBh" style="text-align: right" title="Expected volatility">123.52</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmcOd2SRLADj" style="text-align: right" title="Expected volatility">120.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwysi6ZLJ4bd" style="text-align: right" title="Expected volatility">119.51</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUKLTZyMCxy1" style="text-align: right" title="Expected volatility">119.39</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkwZ4eAm88je" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4HWYfJ9dSy3" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWh0rCAumKCg" style="text-align: right" title="BIOF common stock fair value">0.177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUHXbo6wHkY" style="text-align: right" title="BIOF common stock fair value">0.166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zleVRmi0cgZj" style="text-align: right" title="BIOF common stock fair value">0.154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlKCSMvDfoKe" style="text-align: right" title="BIOF common stock fair value">0.145</td><td style="text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 67%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4/26/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6/5/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">7/13/23</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMW51iEO8fQi" style="width: 13%; text-align: right" title="Risk-free interest rate">3.46</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTBrL3Ug0Bx1" style="width: 13%; text-align: right" title="Risk-free interest rate">3.82</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEXYKsKLdEvf" style="width: 13%; text-align: right" title="Risk-free interest rate">3.82</td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zULfI4iAs1q4" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziiOGCIqg3De" title="Expected life">7</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8mhFRZz9d73" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zboc8JHbfnI6" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9hBLiusTTse" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlugNh12LpE" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGxsU93CmPbk" style="text-align: right" title="Expected volatility">119.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfBlVxYpC4rh" style="text-align: right" title="Expected volatility">103.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z91Pt3Op3qFk" style="text-align: right" title="Expected volatility">90.70</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx5Td0OyoRfa" style="text-align: right" title="BIOF common stock fair value">0.165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0oxL80N7uI8" style="text-align: right" title="BIOF common stock fair value">0.170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUqdE7DJX6Ql" style="text-align: right" title="BIOF common stock fair value">0.160</td><td style="text-align: left"> </td> </tr> </table> 0.0393 0.0377 0.0401 0.0360 0.0330 0.0354 P5Y P10Y P10Y P5Y P10Y P5Y 0 0 0 0 0 0 1.2325 1.2326 1.2352 1.2071 1.1951 1.1939 0.159 0.159 0.177 0.166 0.154 0.145 0.0346 0.0382 0.0382 P5Y P7Y P5Y 0 0 0 1.1928 1.0320 0.9070 0.165 0.170 0.160 <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zVXFUBhNzYth" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zvihgy4MnHt3">Property and Equipment</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__srt--RangeAxis__srt--MinimumMember_zyZj06cKlegh" title="Property and equipment, estimated useful life">5</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__srt--RangeAxis__srt--MaximumMember_z8kHG9lYifJ9" title="Property and equipment, estimated useful life">10</span> years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y P10Y <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zOsfLvrlkGpd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zaZIVqxhF6x4">Patent Capitalization</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $<span id="xdx_90C_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20230630_zD4TCFVM1FCa" title="Patents">234,730</span> as of June 30, 2023 and $<span id="xdx_90B_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20221231_ztKrICflswB" title="Patents">222,109</span> as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 234730 222109 <p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zjf2XNGQ7Ra5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zlCStzD5zQ64">Research and Development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses all research and development costs as incurred. For the six months ended June 30, 2023, and June 30, 2022, the amounts charged to research and development expenses were $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230630_zwm0hloMHhkf" title="Research and development expenses">1,447,276 </span>and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20220630_zHa71dEOgrFa" title="Research and development expenses">1,666,632</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1447276 1666632 <p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zO1BJDE7OuLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zJLjEZUjywji">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persuasive evidence of an arrangement exists;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the product has been shipped or the services have been rendered to the customer;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sales price is fixed or determinable; and,</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collectability is reasonably assured.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_847_ecustom--CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock_zhuCryYJs4vh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_z56DeJZHppse">Common Stock Purchase Warrants and Other Derivative Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zaBxG1enJkK8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zPOoK5VDSxta">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z5CEXsQpk5wl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zUBHznJKrUzj">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zIYVBRzLjmV2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zUvIRwTQcoOg">Profit (Loss) per Common Share:</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcntm7SJtMua" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zOFwEw7q7jGh">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — quoted prices in active markets for identical assets or liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zbWUL9InKw0h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zBWRHW1BdzUe">Recent Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmErIx0gjVk3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_822_zVKHTjSTajD4">PROPERTY AND EQUIPMENT</span></b></span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zfd6wyz7Vylh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z3Ly7YYdCywb" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PROPERTY AND EQUIPMENT</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230630_zzvAFeWBziOg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zOZYs8DqnRk4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zeIUw5S4syzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Building and Improvements</td><td style="width: 2%"> </td> <td style="width: 10%; text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_znThuPs3coZ5" title="Estimated Useful Lives">15</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zdiqbcGZYrr1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Machinery and Equipment</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z3i0Kr0KfSTd" title="Estimated Useful Lives">10</span></td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">791,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">512,450</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zwp7sgtlFw0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and Fixtures</td><td> </td> <td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zONc6LKxSGne" title="Estimated Useful Lives">5</span></td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,649</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zvUzMTX2mGMc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Computer Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zawJ8RXIR1U6" title="Estimated Useful Lives">3</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,824</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,824</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz0SA_zZuVQ4LKm0S5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and Equipment, gross</span></td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">826,383</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">547,293</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzpM5_msPPAENz0SA_zqXau4KLPyhk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(184,283</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(127,178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz0SA_zoHneOVfOptf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Property and Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">642,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">420,115</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zzgduLBeXUd6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total depreciation expense was $<span id="xdx_900_eus-gaap--Depreciation_c20230101__20230630_zy8puMUYotni" title="Depreciation">59,684</span> for the six months ended June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the six months ended June 30, 2023, The Company purchased machinery worth $<span id="xdx_907_eus-gaap--PaymentsToAcquireMachineryAndEquipment_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PilotPlantMember_zzrIns3u7Bdi" title="Purchase of machinery">285,538</span>. This was primarily related to the pilot plant. The Company disposed of machinery that was no longer in use for a total of $<span id="xdx_906_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_zeTpQiT6fxQk" title="Disposal of machinery">3,500</span> that originally was purchased for $<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_ziSu2PhndKS7" title="Purchase value">6,448</span> and that had accumulated depreciation of $<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iI_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_z35iBkRZcNrk" title="Accumulated depreciation">2,579</span>, thereby taking a loss of $<span id="xdx_903_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_zCswIVlPYbq1" title="Loss on disposal of assets">369</span> on the disposal of assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zfd6wyz7Vylh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z3Ly7YYdCywb" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PROPERTY AND EQUIPMENT</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230630_zzvAFeWBziOg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zOZYs8DqnRk4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zeIUw5S4syzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Building and Improvements</td><td style="width: 2%"> </td> <td style="width: 10%; text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_znThuPs3coZ5" title="Estimated Useful Lives">15</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zdiqbcGZYrr1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Machinery and Equipment</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z3i0Kr0KfSTd" title="Estimated Useful Lives">10</span></td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">791,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">512,450</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zwp7sgtlFw0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and Fixtures</td><td> </td> <td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zONc6LKxSGne" title="Estimated Useful Lives">5</span></td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,649</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zvUzMTX2mGMc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Computer Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zawJ8RXIR1U6" title="Estimated Useful Lives">3</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,824</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,824</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz0SA_zZuVQ4LKm0S5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and Equipment, gross</span></td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">826,383</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">547,293</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzpM5_msPPAENz0SA_zqXau4KLPyhk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(184,283</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(127,178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz0SA_zoHneOVfOptf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Property and Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">642,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">420,115</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> P15Y 9370 9370 P10Y 791540 512450 P5Y 13649 13649 P3Y 11824 11824 826383 547293 184283 127178 642100 420115 59684 285538 3500 6448 2579 369 <p id="xdx_804_eus-gaap--IntangibleAssetsDisclosureTextBlock_zDhMgYPLZCgl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_82E_z762bxZ7g7T2">PATENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been granted one patent on its technology and one continuation patent, has filed for three others that are pending, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $<span id="xdx_90A_eus-gaap--FiniteLivedPatentsGross_iI_c20230630_zuG5PhoHDTL3" title="Finite-Lived Patents, Gross">234,730</span> as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 234730 <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zzUnrBXr9evh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_82A_zrTIp2wLpA1e">DEBT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes Payable – Related Parties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $25,000, that is to be repaid when the Company receives an equity investment of at least $3 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 every 12 months instead of interest, with a minimum of 50,000 warrants. It may convert into common stock at $0.13/share at the option of the holder for a total of 192,308 shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $50,000, that is to be repaid when the Company receives $5 million in equity investment. The Note carries a 10% interest per annum. The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $100,000, that if it’s not paid by December 6, 2023, it automatically extends for another 6 months. It’s convertible at the option of the lender into common stock at $0.13/share for a total of 769,231 shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $150,000, that is to be repaid when the Company receives an equity investment of at least $1.5 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 100,000 every 6 months instead of interest. It may convert into common stock at $0.13/share at the option of the holder for a total of 1,153,846 shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $250,000, that if it’s not paid by July 4, 2023, it converts at the option of the Company into common stock at $0.13/share for a total of 1,923,077 shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the notes was $278,794.68. The notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, &amp; Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of future gross revenues to satisfy this note in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes Payable – Other</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the note was $14,382.2. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carried an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $39,500. In May 2018, the company made two principal payments totaling $40,000. The note went into default on June 1, 2018, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to settle both notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $32,000 to $20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zz6wd1KZwgWf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of all debts indicated in the Notes above is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zEZhvlFBySz1" style="display: none">SCHEDULE OF NOTES PAYABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Notes Payable</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230630_z1m9l0ZUAnv8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zXBpWEyiYjo5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_maNPzXA3_zU5jBTeddDEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: left">Short Term Convertible Note – Related Party</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">350,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NotesPayableToBankNoncurrent_iI_pp0p0_maNPzXA3_zzYBZHAG1O2a" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Short Term Chapter 11 Settlement</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LongTermNotesPayableAfterCapitalInvestmentReceived_iI_pp0p0_maNPzXA3_zK3xyFQpEbCg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable after capital investment received</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LongTermNotesPayableFromFutureRevenueRelatedParty_iI_pp0p0_maNPzXA3_zKZzS3XfoXP8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable from future revenue — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--LongTermNotesPayableFromFutureRevenueOther_iI_pp0p0_maNPzXA3_zVF0ONv76Pt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable from future revenue — Other</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LongTermNotePayableFromFutureProfitsRelatedParty_iI_pp0p0_maNPzXA3_zWgdr0ipGzOf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Long Term Note Payable from future profits — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LongTermNotePayableFromFutureProfitsOther_iI_pp0p0_maNPzXA3_ztCFhfqSuWef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long Term Note Payable from future profits — Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayable_iTI_pp0p0_mtNPzXA3_zIuh4XhWy50e" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL NOTES</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,288,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,788,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zpRXXGTrEhfg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the $3,288,132 payable as of June 30, 2023, $2,738,132 is due out of future revenue or future profits with no specific due date, and another $200,000 is due only after a significant capital investment. $2,417,502 of the $2,788,132 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would not be discharged is $670,630, consisting of $550,630 due to related parties, and $120,000 due to others.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zz6wd1KZwgWf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of all debts indicated in the Notes above is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zEZhvlFBySz1" style="display: none">SCHEDULE OF NOTES PAYABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Notes Payable</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230630_z1m9l0ZUAnv8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zXBpWEyiYjo5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_maNPzXA3_zU5jBTeddDEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: left">Short Term Convertible Note – Related Party</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">350,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NotesPayableToBankNoncurrent_iI_pp0p0_maNPzXA3_zzYBZHAG1O2a" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Short Term Chapter 11 Settlement</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LongTermNotesPayableAfterCapitalInvestmentReceived_iI_pp0p0_maNPzXA3_zK3xyFQpEbCg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable after capital investment received</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LongTermNotesPayableFromFutureRevenueRelatedParty_iI_pp0p0_maNPzXA3_zKZzS3XfoXP8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable from future revenue — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--LongTermNotesPayableFromFutureRevenueOther_iI_pp0p0_maNPzXA3_zVF0ONv76Pt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Long Term Notes Payable from future revenue — Other</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LongTermNotePayableFromFutureProfitsRelatedParty_iI_pp0p0_maNPzXA3_zWgdr0ipGzOf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Long Term Note Payable from future profits — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LongTermNotePayableFromFutureProfitsOther_iI_pp0p0_maNPzXA3_ztCFhfqSuWef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long Term Note Payable from future profits — Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayable_iTI_pp0p0_mtNPzXA3_zIuh4XhWy50e" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL NOTES</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,288,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,788,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 350000 0 0 50000 200000 0 1700630 1700630 120000 120000 820932 820932 96570 96570 3288132 2788132 <p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zPOSl8krZNp1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_827_zXHfs9Jy1XEk">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares of capital stock, which the Company has authority to issue, is <span id="xdx_905_eus-gaap--CapitalUnitsAuthorized_iI_pn6n6_c20230630_zNXprD7WManf" title="Capital units, authorized">1,010</span> million, <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pn9n9_c20230630_z12OEf5YwVGg" title="Common stock, shares authorized">1</span> billion of which are designated as common stock at $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230630_zfV9mw5Dvooj" title="Common stock, par value">0.001</span> par value (the “Common Stock”) and <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pn6n6_c20230630_zln9nFMNWtze" title="Preferred stock, shares authorized">10</span> million of which are designated as preferred stock par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230630_zlb4A1mLe892" title="Preferred stock, par value">0.001</span> (the “Preferred Stock”). As of June 30, 2023, the Company had <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pid_c20230630_zMbNTLapRKZ2" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230630_zVKqjvNkpnq5" title="Common stock, shares outstanding">300,584,297</span></span> shares of Common Stock issued and outstanding and <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20230630_z0JzonW6Ppza" title="Preferred stock, shares Issued">no</span> shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2023, the Company issued an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230630_zLCdxADfVGjc" title="Number of shares issued for services, shares">174,191</span> shares of its common stock for services valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20230101__20230630_zfrl0YR82aPj" title="Number of shares issued for services, value">29,300</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2023, <span id="xdx_907_ecustom--WarrantsIssuedForService_c20230101__20230630_zDU2UYpuApS1" title="Warrants issued for services">314,000</span> warrants were issued for services. Using a Black-Scholes asset pricing model, these had a value of $<span id="xdx_900_ecustom--WarrantsIssuedDuringPeriodValueIssuedForServices_c20230101__20230630_z0r6kIVJD8y1" title="Warrants issued for services, value">42,634</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2023, <span id="xdx_902_ecustom--IssuanceOfCommonStockAndWarrantsForCashThroughPpmShares_c20230101__20230630_zlOkDXQmatne" title="Issuance of common stock and warrants for cash through PPM, shares">4,518,332</span> shares of common stock were issued for cash of $<span id="xdx_90A_ecustom--IssuanceOfCommonStockAndWarrantsForCashThroughPpm_pp0p0_c20230101__20230630_zN5lJOuxaSDe" title="Issuance of common stock and warrants for cash through PPM">677,771</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2023, <span id="xdx_905_ecustom--WarrantsExercisedShare_c20230101__20230630_z3ID7AkRvAW5" title="Warrants exercised share, shares">5,950,148</span> warrants were exercised for proceeds of $<span id="xdx_90E_ecustom--WarrantsExercised_c20230101__20230630_zHoC1Hcc1Ru4" title="Warrants exercised">97,250</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2023, <span id="xdx_901_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20230101__20230630_zb61iDErNP09" title="Number of warrants expired">2,067,999</span> warrants expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2023, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20230630_zyVfTTIjfGN" title="Unvested options expired">7,050,000</span> unvested options expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2023, <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20230630_zZbZxY1MIuU8" title="Number of stock options vested, shares">4,385,000</span> stock options vested. Using a Black-Scholes asset pricing model, these had a value of $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20230101__20230630_zCL25mUH5QO1" title="Number of stock options vested, value">637,028</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2023, <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20230630_zKpvDpsNgpMc" title="Number of shares unvested">15,950,000</span> stock options were issued and unvested. Using a Black-Scholes asset pricing model, these have a value of $<span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedAndUnvestedInPeriodFairValue_c20230101__20230630_zf2sLZM1M852" title="Options issued and unvested value">2,675,116</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1010000000 1000000000 0.001 10000000 0.001 300584297 300584297 0 174191 29300 314000 42634 4518332 677771 5950148 97250 2067999 7050000 4385000 637028 15950000 2675116 <p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zgb4H4y62GRk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 - <span id="xdx_823_z5VeJeHWKBc6">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. The Company is not in any litigation at this time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period was for twenty-four (24) months from November 1, 2019, to October 31, 2021. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zDRGmNY1ztF5" title="Lease extension period">This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024.</span> Annual rent commenced at $<span id="xdx_907_ecustom--AnnualRent_pp0p0_c20230101__20230630_zeF6ieybPqa1" title="Annual rent">84,100</span> per annum and increased <span id="xdx_908_ecustom--PercentageOfIncreaseInRentPerYear_pid_dp_uPure_c20230101__20230630_zVxNLxl83Ks4" title="Percentage of increase in rent per year">3%</span> per year. The latest amendment adjusted to lease to $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_pp0p0_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zgXCYnf2D13g" title="Lease expense">102,950</span> per annum and increases at <span id="xdx_903_ecustom--PercentageOfIncreaseInRentPerYear_pid_dp_uPure_c20230101__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zdsuR2Q8o4ik" title="Percentage of increase in rent per year">3%</span> per year. Tenant is also required to cover operating costs that are estimated at $<span id="xdx_905_eus-gaap--OperatingLeaseCost_pp0p0_c20230101__20230630_zZe82daTbg3f" title="Operating costs">3,600</span> per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General &amp; Administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company leases land in Arcadia, FL where it grows king grass. The original lease began on September 1, 2020, and was for <span id="xdx_905_eus-gaap--AreaOfLand_iI_uAcres_c20200901_zgejzjBUmX72" title="Acres">18.2</span> acres at an annual cost of $<span id="xdx_906_eus-gaap--LeaseCost_c20200901__20200901_z5SC1PDeOIY4" title="Lease cost">6,370</span> that the Company has the right to renew for a total of <span id="xdx_902_ecustom--LeaseRenewalTerm_dtY_c20200901__20200901_z7JABmUa2qrl" title="Lease renewal term">5</span> years. A second lease began on March 31, 2023, for an additional <span id="xdx_90C_eus-gaap--AreaOfLand_iI_uAcres_c20230630_zXO5m8Je3JXh" title="Acres">167.6</span> acres at a cost of $<span id="xdx_90C_eus-gaap--LeaseCost_c20230101__20230630_zAhWgsFXfFTj" title="Lease cost">24,721</span> every 6 months that the Company also can continue for up to <span id="xdx_90F_ecustom--LeaseRenewalTerm_dtY_c20230101__20230630_z7eEbw9qoIvl" title="Lease renewal term">5</span> years. Since those leases can be terminated at will, they are not included in the ROU or lease liability on the Company’s balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent expense for the six months ending June 30, 2023, and 2022, were $<span id="xdx_902_eus-gaap--PaymentsForRent_c20230101__20230630_zaSk8LKEq9ag" title="Rent expense">108,893</span> and $<span id="xdx_902_eus-gaap--PaymentsForRent_c20220101__20220630_z1SLHGU6FTtc" title="Rent expense">64,724</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zpBMd6z2Kbvg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized the following related to leases in its Consolidated Balance Sheet:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> <span id="xdx_8B6_z9XkI8nN8GI6" style="display: none">SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PERIOD ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230630_zKPq5pnAwoXi" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zkYh8UyVNvVf" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right of Use Lease Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzR4B_z5NfUqfR6Hkc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 56%; text-align: left">Current portion</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">99,626</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">95,172</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzR4B_zcTOqxtHM9Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,909</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzR4B_zoF3iZQc25Mb" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">134,535</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">181,155</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z55l0Dhj8Qc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z6SzHgpSLlDa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> <span id="xdx_8B8_zcgysf2Zv2Yi" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">YEAR ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230630_z6cNzxzSYvS2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MINIMUM</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DUE</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_za13JpsTEI04" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: right">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">48,552</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_ztgc0UNxLB08" style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,983</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_z45ezKHJCTse" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zVZlhrI97ZN4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">134,535</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AE_z6kcEelNxKv8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024. 84100 0.03 102950 0.03 3600 18.2 6370 P5Y 167.6 24721 P5Y 108893 64724 <p id="xdx_895_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zpBMd6z2Kbvg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized the following related to leases in its Consolidated Balance Sheet:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> <span id="xdx_8B6_z9XkI8nN8GI6" style="display: none">SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PERIOD ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230630_zKPq5pnAwoXi" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zkYh8UyVNvVf" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right of Use Lease Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzR4B_z5NfUqfR6Hkc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 56%; text-align: left">Current portion</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">99,626</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">95,172</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzR4B_zcTOqxtHM9Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,909</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzR4B_zoF3iZQc25Mb" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">134,535</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">181,155</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 99626 95172 34909 85983 134535 181155 <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z6SzHgpSLlDa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> <span id="xdx_8B8_zcgysf2Zv2Yi" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">YEAR ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230630_z6cNzxzSYvS2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MINIMUM</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DUE</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_za13JpsTEI04" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: right">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">48,552</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_ztgc0UNxLB08" style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,983</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_z45ezKHJCTse" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zVZlhrI97ZN4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">134,535</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 48552 85983 0 134535 <p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHgOEjXOIkvc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_821_z1qWT7KlVehc">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Party Transactions</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 6.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they continued to receive less than full salaries.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zQRxmcVDcTP1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_826_z4EhYuuAAQd2">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From July 1, 2023, to the date of this filing, the Company received an SBIR Phase I grant from the Department of Energy valued at $<span id="xdx_904_ecustom--GrantsReceived_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ProductOrServiceAxis__custom--SBIRPhaseIGrantMember_zjj61nCgKQpf" title="SBIR phase I grants">206,500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From July 1, 2023, to the date of this filing, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKT3du0iKOVb" title="Shares issued for services">0</span> shares for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From July 1, 2023, to the date of this filing, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeWVdbH6YrX8" title="Stock options expired">125,000</span> options expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From July 1, 2023, to the date of this filing, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUrFTDt20Czi" title="Number of unvested shares issued">1,200,000</span> unvested options were issued at an exercise price of <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice_pid_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkJMX43vA6E8" title="Exercise price">16</span> cents per share and expiration dates of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zFBwvCd3ayu" title="Expiration date">5</span> and <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_z9mPLdNbW6E9" title="Expiration date">10</span> years. Using the Black-Scholes option pricing model, they were valued at $<span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesValue_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUqtpTyTsLGj" title="Number of unvested shares issued, value">160,497</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From July 1, 2023, to the date of this filing, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlhi8ssPxYS3" title="Number of shares issued for private placement">500,000</span> shares in a private placement for proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmSX06pO8oxk" title="Proceeds from issuance of private placement">75,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From July 1, 2023, to the date of this filing, the Company issued convertible notes to related parties for $<span id="xdx_903_eus-gaap--ConvertibleDebt_iI_c20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zWsCm7FozzRe" title="Convertible note">25,000</span>. Instead of interest, it accrues warrants at the rate of <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_z4S6Fxi0IYy2" title="Conversion of convertible note into shares">50,000</span> per year. Those warrants were valued at $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20230701__20230701__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zb2YsmO3reT9" title="Warrants valued">5,812</span> using the Black Scholes option pricing model.</span></p> 206500 0 125000 1200000 16 P5Y P10Y 160497 500000 75000 25000 50000 5812 EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 101 202 1 false 27 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://bluebiofuels.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://bluebiofuels.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://bluebiofuels.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statement of Operations (Unaudited) Sheet http://bluebiofuels.com/role/StatementOfOperations Consolidated Statement of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Sheet http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://bluebiofuels.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - ORGANIZATION Sheet http://bluebiofuels.com/role/Organization ORGANIZATION Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://bluebiofuels.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://bluebiofuels.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 00000012 - Disclosure - PATENTS Sheet http://bluebiofuels.com/role/Patents PATENTS Notes 12 false false R13.htm 00000013 - Disclosure - DEBT Sheet http://bluebiofuels.com/role/Debt DEBT Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://bluebiofuels.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://bluebiofuels.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://bluebiofuels.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://bluebiofuels.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://bluebiofuels.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://bluebiofuels.com/role/PropertyAndEquipment 20 false false R21.htm 00000021 - Disclosure - DEBT (Tables) Sheet http://bluebiofuels.com/role/DebtTables DEBT (Tables) Tables http://bluebiofuels.com/role/Debt 21 false false R22.htm 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://bluebiofuels.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://bluebiofuels.com/role/CommitmentsAndContingencies 22 false false R23.htm 00000023 - Disclosure - ORGANIZATION (Details Narrative) Sheet http://bluebiofuels.com/role/OrganizationDetailsNarrative ORGANIZATION (Details Narrative) Details http://bluebiofuels.com/role/Organization 23 false false R24.htm 00000024 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://bluebiofuels.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://bluebiofuels.com/role/GoingConcern 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) Sheet http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) Details 25 false false R26.htm 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 27 false false R28.htm 00000028 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://bluebiofuels.com/role/PropertyAndEquipmentTables 28 false false R29.htm 00000029 - Disclosure - PATENTS (Details Narrative) Sheet http://bluebiofuels.com/role/PatentsDetailsNarrative PATENTS (Details Narrative) Details http://bluebiofuels.com/role/Patents 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 30 false false R31.htm 00000031 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://bluebiofuels.com/role/StockholdersEquity 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details) Sheet http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details) Details 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details) Sheet http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details) Details 33 false false R34.htm 00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://bluebiofuels.com/role/CommitmentsAndContingenciesTables 34 false false R35.htm 00000035 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://bluebiofuels.com/role/SubsequentEvents 35 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentQuarterlyReport, dei:DocumentTransitionReport - form10-q.htm 29, 30 form10-q.htm biof-20230630.xsd biof-20230630_cal.xml biof-20230630_def.xml biof-20230630_lab.xml biof-20230630_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 7, "baseTaxonomies": { "http://fasb.org/srt/2023": 1, "http://fasb.org/us-gaap/2023": 443, "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 101, "dts": { "calculationLink": { "local": [ "biof-20230630_cal.xml" ] }, "definitionLink": { "local": [ "biof-20230630_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "biof-20230630_lab.xml" ] }, "presentationLink": { "local": [ "biof-20230630_pre.xml" ] }, "schema": { "local": [ "biof-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 314, "entityCount": 1, "hidden": { "http://bluebiofuels.com/20230630": 18, "http://fasb.org/us-gaap/2023": 45, "http://xbrl.sec.gov/dei/2023": 6, "total": 69 }, "keyCustom": 28, "keyStandard": 174, "memberCustom": 13, "memberStandard": 14, "nsprefix": "BIOF", "nsuri": "http://bluebiofuels.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bluebiofuels.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "10", "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PROPERTY AND EQUIPMENT", "menuCat": "Notes", "order": "11", "role": "http://bluebiofuels.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - PATENTS", "menuCat": "Notes", "order": "12", "role": "http://bluebiofuels.com/role/Patents", "shortName": "PATENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - DEBT", "menuCat": "Notes", "order": "13", "role": "http://bluebiofuels.com/role/Debt", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "menuCat": "Notes", "order": "14", "role": "http://bluebiofuels.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "15", "role": "http://bluebiofuels.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "16", "role": "http://bluebiofuels.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "17", "role": "http://bluebiofuels.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "18", "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "19", "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://bluebiofuels.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "menuCat": "Tables", "order": "20", "role": "http://bluebiofuels.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - DEBT (Tables)", "menuCat": "Tables", "order": "21", "role": "http://bluebiofuels.com/role/DebtTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "menuCat": "Tables", "order": "22", "role": "http://bluebiofuels.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "BIOF:RenewableFuelDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - ORGANIZATION (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://bluebiofuels.com/role/OrganizationDetailsNarrative", "shortName": "ORGANIZATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "BIOF:RenewableFuelDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - GOING CONCERN (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://bluebiofuels.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-06-30_custom_IssuanceDateFebruaryTenTwoThousandTwentyThreeMember_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details)", "menuCat": "Details", "order": "25", "role": "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails", "shortName": "SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-06-30_custom_IssuanceDateFebruaryTenTwoThousandTwentyThreeMember_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "menuCat": "Details", "order": "27", "role": "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30_us-gaap_BuildingImprovementsMember", "decimals": "0", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - PATENTS (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://bluebiofuels.com/role/PatentsDetailsNarrative", "shortName": "PATENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "menuCat": "Details", "order": "30", "role": "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "menuCat": "Details", "order": "31", "role": "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "lang": null, "name": "BIOF:WarrantsIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details)", "menuCat": "Details", "order": "32", "role": "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails", "shortName": "SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)", "menuCat": "Details", "order": "33", "role": "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails", "shortName": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "BIOF:AnnualRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "BIOF:AnnualRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-07-012023-07-01_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statement of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://bluebiofuels.com/role/StatementOfOperations", "shortName": "Consolidated Statement of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://bluebiofuels.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - ORGANIZATION", "menuCat": "Notes", "order": "8", "role": "http://bluebiofuels.com/role/Organization", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - GOING CONCERN", "menuCat": "Notes", "order": "9", "role": "http://bluebiofuels.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 27, "tag": { "BIOF_AnnualRent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Annual rent.", "label": "Annual rent" } } }, "localname": "AnnualRent", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BIOF_CashlessConversionOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless conversion of warrants.", "label": "Cashless conversion of warrants/options" } } }, "localname": "CashlessConversionOfWarrants", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIOF_CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Purchase Warrants And Other Derivative Financia lInstruments [Policy Text Block].", "label": "Common Stock Purchase Warrants and Other Derivative Financial Instruments" } } }, "localname": "CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BIOF_ConversionOfConvertibleDebentureToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of convertible debenture to common stock.", "label": "Conversion of convertible debenture to common stock" } } }, "localname": "ConversionOfConvertibleDebentureToCommonStock", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIOF_GrantsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Grants received.", "label": "SBIR phase I grants" } } }, "localname": "GrantsReceived", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BIOF_IncreaseDecreaseInRightOfUseLease": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in right of use lease.", "label": "Right of use lease" } } }, "localname": "IncreaseDecreaseInRightOfUseLease", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIOF_IssuanceDateAprilElevenTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date April Eleven Two Thousand Twenty Three [Member]", "label": "Issuance Date 4/11/23 [Member]" } } }, "localname": "IssuanceDateAprilElevenTwoThousandTwentyThreeMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceDateAprilFiveTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date April Five Two Thousand Twenty Three [Member]", "label": "Issuance Date 4/5/23 [Member]" } } }, "localname": "IssuanceDateAprilFiveTwoThousandTwentyThreeMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date April Twenty Six Two Thousand Twenty Three [Member]", "label": "Issuance Date 4/26/23 [Member]" } } }, "localname": "IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date February Fourteen Two Thousand Twenty Three [Member]", "label": "Issuance Date 2/14/23 [Member]" } } }, "localname": "IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceDateFebruaryTenTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date February Ten Two Thousand Twenty Three [Member]", "label": "Issuance Date 2/10/23 [Member]" } } }, "localname": "IssuanceDateFebruaryTenTwoThousandTwentyThreeMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceDateJulyThirteenTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date July Thirteen Two Thousand Twenty Three [Member]", "label": "Issuance Date 7/13/23 [Member]" } } }, "localname": "IssuanceDateJulyThirteenTwoThousandTwentyThreeMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceDateJuneFiveTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date June Five Two Thousand Twenty Three [Member]", "label": "Issuance Date 6/5/23 [Member]" } } }, "localname": "IssuanceDateJuneFiveTwoThousandTwentyThreeMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceDateMarchOneTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date March One Two Thousand Twenty Three [Member]", "label": "Issuance Date 3/1/23 [Member]" } } }, "localname": "IssuanceDateMarchOneTwoThousandTwentyThreeMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance Date March Thirty First Two Thousand Twenty Three [Member]", "label": "Issuance Date 3/31/2023 [Member]" } } }, "localname": "IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "BIOF_IssuanceOfCommonStockAndWarrantsForCashThroughPpm": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and warrants for cash through ppm.", "label": "Issuance of common stock and warrants for cash through PPM" } } }, "localname": "IssuanceOfCommonStockAndWarrantsForCashThroughPpm", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BIOF_IssuanceOfCommonStockAndWarrantsForCashThroughPpmShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and warrants for cash through Ppm shares.", "label": "Issuance of common stock and warrants for cash through PPM, shares" } } }, "localname": "IssuanceOfCommonStockAndWarrantsForCashThroughPpmShares", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BIOF_LeaseRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease renewal term.", "label": "Lease renewal term" } } }, "localname": "LeaseRenewalTerm", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "BIOF_LongTermNotePayableFromFutureProfitsOther": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 7.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term note payable from future profits other.", "label": "Long Term Note Payable from future profits \u2014 Other" } } }, "localname": "LongTermNotePayableFromFutureProfitsOther", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BIOF_LongTermNotePayableFromFutureProfitsRelatedParty": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 6.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term note payable from future profits related party.", "label": "Long Term Note Payable from future profits \u2014 Related Party" } } }, "localname": "LongTermNotePayableFromFutureProfitsRelatedParty", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BIOF_LongTermNotesPayableAfterCapitalInvestmentReceived": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 3.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term notes payable after capital investment received.", "label": "Long Term Notes Payable after capital investment received" } } }, "localname": "LongTermNotesPayableAfterCapitalInvestmentReceived", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BIOF_LongTermNotesPayableFromFutureRevenueOther": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 5.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long Term Notes Payable From Future Revenue Other.", "label": "Long Term Notes Payable from future revenue \u2014 Other" } } }, "localname": "LongTermNotesPayableFromFutureRevenueOther", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BIOF_LongTermNotesPayableFromFutureRevenueRelatedParty": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 4.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term notes payable from future revenue related party.", "label": "Long Term Notes Payable from future revenue \u2014 Related Party" } } }, "localname": "LongTermNotesPayableFromFutureRevenueRelatedParty", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BIOF_MachineryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Machinery [Member]", "label": "Machinery [Member]" } } }, "localname": "MachineryMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "BIOF_OfficeAndLaboratorySpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and Laboratory Space [Member]", "label": "Office and Laboratory Space [Member]" } } }, "localname": "OfficeAndLaboratorySpaceMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BIOF_PaymentsForPatentCosts": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for patent costs.", "label": "PaymentsForPatentCosts", "negatedLabel": "Patent Costs" } } }, "localname": "PaymentsForPatentCosts", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIOF_PercentageOfIncreaseInRentPerYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in rent per year.", "label": "Percentage of increase in rent per year" } } }, "localname": "PercentageOfIncreaseInRentPerYear", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "BIOF_PilotPlantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pilot Plant [Member]", "label": "Pilot Plant [Member]" } } }, "localname": "PilotPlantMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "BIOF_RenewableFuelDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renewable Fuel Description.", "label": "Renewable fuel description" } } }, "localname": "RenewableFuelDescription", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "BIOF_SBIRPhaseIGrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SBIR Phase I Grant [Member]", "label": "SBIR Phase I Grant [Member]" } } }, "localname": "SBIRPhaseIGrantMember", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BIOF_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options issued in period weighted average exercise price.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "BIOF_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedAndUnvestedInPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award options issued and unvested in period fair value.", "label": "Options issued and unvested value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedAndUnvestedInPeriodFairValue", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BIOF_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested number of shares value.", "label": "Number of unvested shares issued, value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesValue", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BIOF_StockIssuedDuringPeriodSharesStockOptionsExercised1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised.", "label": "Employee stock options exercised, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "BIOF_StockIssuedDuringPeriodValueStockOptionsExercised1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised1.", "label": "Employee stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised1", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "BIOF_StockbasedCompensationValuationMethodologyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockbased Compensation Valuation Methodology [Policy Text Block]", "label": "Stock-based Compensation Valuation Methodology" } } }, "localname": "StockbasedCompensationValuationMethodologyPolicyTextBlock", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BIOF_StockholdersEquityDeficit": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders Equity Deficit.", "label": "Stockholders Equity Deficit", "totalLabel": "TOTAL EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityDeficit", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "BIOF_WarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants exercised.", "label": "Warrants exercised" } } }, "localname": "WarrantsExercised", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BIOF_WarrantsExercisedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants exercised share.", "label": "Warrants exercised, shares", "verboseLabel": "Warrants exercised share, shares" } } }, "localname": "WarrantsExercisedShare", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BIOF_WarrantsIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued during period value issued for services.", "label": "Warrants issued for services, value" } } }, "localname": "WarrantsIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BIOF_WarrantsIssuedForService": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants issued for service.", "label": "Warrants issued for services" } } }, "localname": "WarrantsIssuedForService", "nsuri": "http://bluebiofuels.com/20230630", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r466", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r217", "r313", "r339", "r356", "r357", "r415", "r416", "r417", "r418", "r419", "r423", "r424", "r434", "r437", "r439", "r444", "r495", "r530", "r531", "r532", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r217", "r313", "r339", "r356", "r357", "r415", "r416", "r417", "r418", "r419", "r423", "r424", "r434", "r437", "r439", "r444", "r495", "r530", "r531", "r532", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r155", "r317", "r333", "r334", "r335", "r336", "r337", "r338", "r426", "r438", "r443", "r475", "r491", "r492", "r496", "r538" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r155", "r317", "r333", "r334", "r335", "r336", "r337", "r338", "r426", "r438", "r443", "r475", "r491", "r492", "r496", "r538" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services." } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r166", "r167", "r168", "r169", "r216", "r217", "r247", "r248", "r249", "r312", "r313", "r339", "r356", "r357", "r415", "r416", "r417", "r418", "r419", "r423", "r424", "r434", "r437", "r439", "r444", "r447", "r489", "r495", "r531", "r532", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r216", "r217", "r247", "r248", "r249", "r312", "r313", "r339", "r356", "r357", "r415", "r416", "r417", "r418", "r419", "r423", "r424", "r434", "r437", "r439", "r444", "r447", "r489", "r495", "r531", "r532", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "auth_ref": [ "r476", "r484" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET" } } }, "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r12", "r442" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r33", "r99", "r327" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated depreciation and amortization on property and equipment", "negatedLabel": "Less Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r53", "r442", "r540" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r252", "r253", "r254", "r354", "r485", "r486", "r487", "r523", "r541" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r39", "r40", "r220" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Vesting of options under the employee, director plan" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r7", "r34", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of 314,000 warrants for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r251", "r259" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock based compensation for services" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Acres" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r100", "r118", "r143", "r149", "r153", "r158", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r272", "r274", "r286", "r321", "r377", "r442", "r454", "r493", "r494", "r528" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r95", "r102", "r118", "r158", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r272", "r274", "r286", "r442", "r493", "r494", "r528" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r118", "r158", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r272", "r274", "r286", "r493", "r494", "r528" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "TOTAL OTHER ASSETS" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingImprovementsMember": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building Improvements [Member]" } } }, "localname": "BuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalUnitsAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital units, authorized" } } }, "localname": "CapitalUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r20", "r97", "r427" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r20", "r64", "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalent at end of the period", "periodStartLabel": "Cash and cash equivalent at beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r64" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r73", "r164", "r165", "r422", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r445", "r446", "r447", "r449", "r450", "r451", "r452", "r485", "r486", "r523", "r539", "r541" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r52", "r365" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r52", "r365", "r383", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r52", "r323", "r442" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; $0.001 par value; 1,000,000,000 shares authorized; 300,584,297 issued and outstanding at June 30, 2023, and 289,941,623 shares issued and outstanding at December 31, 2022." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r41", "r429" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r23", "r24", "r25" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of convertible note into shares" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r10", "r80", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible note" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 1.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Short Term Convertible Note \u2013 Related Party" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r23", "r25" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Warrants valued" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r74", "r116", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r5", "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r5", "r32" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r109", "r126", "r127", "r128", "r129", "r130", "r134", "r136", "r138", "r139", "r140", "r141", "r284", "r285", "r319", "r331", "r431" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net income (loss) per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r109", "r126", "r127", "r128", "r129", "r130", "r136", "r138", "r139", "r140", "r141", "r284", "r285", "r319", "r331", "r431" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net income (loss) per share, fully diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Profit (Loss) per Common Share:" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r7", "r93", "r106", "r107", "r108", "r121", "r122", "r123", "r125", "r131", "r133", "r142", "r159", "r160", "r205", "r252", "r253", "r254", "r269", "r270", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r287", "r288", "r289", "r290", "r291", "r292", "r300", "r340", "r341", "r342", "r354", "r407" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r69" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Patents", "verboseLabel": "Finite-Lived Patents, Gross" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/PatentsDetailsNarrative", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r480" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 }, "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss on disposal of assets", "negatedTerseLabel": "Loss on Disposal of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Loss on disposal of assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r5", "r35", "r36" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r59", "r387" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r72" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r78", "r118", "r124", "r143", "r148", "r152", "r154", "r158", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r285", "r286", "r329", "r433", "r493" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Income (Loss) before provisions for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r91", "r132", "r133", "r146", "r264", "r271", "r332" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provisions for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r105", "r262", "r263", "r265", "r266", "r267", "r268", "r348" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r4" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Accrued interest - related party" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r4" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "PATENTS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/Patents" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r31", "r314", "r315", "r316", "r318", "r430" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Patent Capitalization" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r61", "r187", "r191", "r435", "r436" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expense - related party" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest expense - other" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r110", "r112", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable - Related Party" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r5" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Net Issuance of options and warrants for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r297", "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "TOTAL" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lease extension period" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r118", "r158", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r273", "r274", "r275", "r286", "r364", "r432", "r454", "r493", "r528", "r529" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r57", "r81", "r325", "r442", "r481", "r488", "r524" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r96", "r118", "r158", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r273", "r274", "r275", "r286", "r442", "r493", "r528", "r529" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r10", "r47", "r48", "r49", "r50", "r118", "r158", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r273", "r274", "r275", "r286", "r493", "r528", "r529" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "TOTAL LONG TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r17" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable \u2014 Related Party" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash from (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r65", "r66" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r58", "r66", "r82", "r94", "r103", "r104", "r108", "r118", "r124", "r126", "r127", "r128", "r129", "r132", "r133", "r137", "r143", "r148", "r152", "r154", "r158", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r285", "r286", "r330", "r385", "r405", "r406", "r433", "r453", "r493" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "totalLabel": "Net Income / (Loss):" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/StatementsOfCashFlows", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental schedule of non-cash activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other (income) expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonrelatedPartyMember": { "auth_ref": [ "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Party not related to reporting entity.", "label": "Nonrelated Party [Member]" } } }, "localname": "NonrelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r10", "r80", "r537" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "totalLabel": "TOTAL NOTES" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Convertible Notes Payable \u2014 Related Party" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBankCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.", "label": "Chapter 11 Settlement" } } }, "localname": "NotesPayableToBankCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBankNoncurrent": { "auth_ref": [ "r10", "r80" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "order": 2.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount due within more than 12 month, or the operating cycle if longer, on all notes payable to banks paid on an installment. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.", "label": "Short Term Chapter 11 Settlement" } } }, "localname": "NotesPayableToBankNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expense:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r143", "r148", "r152", "r154", "r433" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations:" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r298", "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r525" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r295" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "TOTAL" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r295" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease Liability - Current", "verboseLabel": "Current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r295" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Right of Use Lease Liability, net of current portion", "verboseLabel": "Long-term portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r294" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of Use Assets, net of accumulated amortization" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r45", "r77", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r15", "r442" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Deferred wages and director\u2019s fees - Related party" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermNotesPayable": { "auth_ref": [ "r17" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.", "label": "Notes Payable \u2014 Other" } } }, "localname": "OtherLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) expense:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForOtherDeposits": { "auth_ref": [ "r478" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for deposits classified as other.", "label": "Payments for Other Deposits", "negatedLabel": "Security deposits" } } }, "localname": "PaymentsForOtherDeposits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Rent expense" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of machinery and equipment.", "label": "Purchase of machinery" } } }, "localname": "PaymentsToAcquireMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r63" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Net Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r445", "r446", "r449", "r450", "r451", "r452", "r539", "r541" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r51", "r193" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r51", "r365" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r51", "r193" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock, shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r51", "r365", "r383", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r51", "r322", "r442" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r101", "r161", "r162", "r428" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r19" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Net Proceeds from the issuance of Convertible Notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r2" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from issuance of private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Disposal of machinery" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r479" ], "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants and options" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r70", "r86", "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r71", "r98", "r328" ], "calculation": { "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and Equipment, gross", "verboseLabel": "Purchase value" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r6", "r320", "r328", "r442" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net of accumulated depreciation and amortization of $184,283 and $127,178 at June 30, 2023 and December 31,2022, respectively", "totalLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r6", "r86", "r89", "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property and equipment, estimated useful life", "verboseLabel": "Estimated Useful Lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r119", "r120", "r304", "r305", "r306", "r307", "r359", "r360", "r361", "r362", "r363", "r382", "r384", "r414" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r304", "r305", "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r388", "r389", "r392" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r301", "r302", "r303", "r305", "r308", "r351", "r352", "r353", "r390", "r391", "r392", "r411", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r44", "r261", "r536" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research & Development", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r54", "r76", "r324", "r343", "r344", "r350", "r366", "r442" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Accumulated losses" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r93", "r121", "r122", "r123", "r125", "r131", "r133", "r159", "r160", "r252", "r253", "r254", "r269", "r270", "r276", "r278", "r279", "r281", "r283", "r340", "r342", "r354", "r541" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r144", "r145", "r147", "r150", "r151", "r155", "r156", "r157", "r214", "r215", "r317" ], "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r92", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF NOTES PAYABLE" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r42", "r43", "r388", "r389", "r392" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r8", "r9", "r38" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r219", "r221", "r222", "r223", "r224", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r477" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security deposits" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r219", "r221", "r222", "r223", "r224", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Unvested options expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Number of unvested shares issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r218", "r225", "r244", "r245", "r246", "r247", "r250", "r255", "r256", "r257", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "BIOF common stock fair value" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Expiration date" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Number of shares unvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Number of stock options vested, value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Vesting of options previously issued under employee director plan", "verboseLabel": "Number of stock options vested, shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r67", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r7", "r18", "r93", "r106", "r107", "r108", "r121", "r122", "r123", "r125", "r131", "r133", "r142", "r159", "r160", "r205", "r252", "r253", "r254", "r269", "r270", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r287", "r288", "r289", "r290", "r291", "r292", "r300", "r340", "r341", "r342", "r354", "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r121", "r122", "r123", "r142", "r317", "r347", "r355", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r384", "r386", "r387", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r407", "r448" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r121", "r122", "r123", "r142", "r317", "r347", "r355", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r384", "r386", "r387", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r407", "r448" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of common stock for services, shares", "terseLabel": "Shares issued for services", "verboseLabel": "Number of shares issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r51", "r52", "r76", "r349", "r407", "r420" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of shares issued for private placement" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r51", "r52", "r76", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock options expired" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of common stock for services", "verboseLabel": "Number of shares issued for services, value" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r7", "r51", "r52", "r76" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Number of warrants expired" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r52", "r55", "r56", "r68", "r367", "r383", "r408", "r409", "r442", "r454", "r481", "r488", "r524", "r541" ], "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "order": 1.0, "parentTag": "BIOF_StockholdersEquityDeficit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r75", "r117", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r282", "r410", "r412", "r421" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r293", "r310" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r293", "r310" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r293", "r310" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r293", "r310" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r293", "r310" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r309", "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid during the period for" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r28", "r29", "r30", "r84", "r85", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r445", "r446", "r449", "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r135", "r140" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Fully Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r134", "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(1),20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//350-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r456": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r457": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r458": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r459": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r461": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r466": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r467": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r468": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r469": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r471": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r472": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r473": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r474": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 54 0001493152-23-026996-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-026996-xbrl.zip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end